CN110234314A - The method of dry acellular tissue extract and the dried hydrogel comprising nanometer fibril cellulose and acellular tissue extract in the hydrogel comprising nanometer fibril cellulose - Google Patents
The method of dry acellular tissue extract and the dried hydrogel comprising nanometer fibril cellulose and acellular tissue extract in the hydrogel comprising nanometer fibril cellulose Download PDFInfo
- Publication number
- CN110234314A CN110234314A CN201780078102.7A CN201780078102A CN110234314A CN 110234314 A CN110234314 A CN 110234314A CN 201780078102 A CN201780078102 A CN 201780078102A CN 110234314 A CN110234314 A CN 110234314A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- nanometer fibril
- fibril cellulose
- tissue extract
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002678 cellulose Polymers 0.000 title claims abstract description 215
- 239000001913 cellulose Substances 0.000 title claims abstract description 214
- 239000000017 hydrogel Substances 0.000 title claims abstract description 185
- 239000000284 extract Substances 0.000 title claims abstract description 168
- 238000000034 method Methods 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 74
- 239000000126 substance Substances 0.000 claims abstract description 62
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 55
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 54
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 53
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 50
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 50
- 230000000975 bioactive effect Effects 0.000 claims abstract description 31
- 210000001519 tissue Anatomy 0.000 claims description 152
- 210000000577 adipose tissue Anatomy 0.000 claims description 40
- 239000000499 gel Substances 0.000 claims description 39
- 238000004108 freeze drying Methods 0.000 claims description 34
- 238000001035 drying Methods 0.000 claims description 30
- 230000003647 oxidation Effects 0.000 claims description 18
- 238000007254 oxidation reaction Methods 0.000 claims description 18
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 17
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 claims description 10
- 239000003292 glue Substances 0.000 claims description 8
- 239000003636 conditioned culture medium Substances 0.000 claims description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 230000002045 lasting effect Effects 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 description 183
- 210000004027 cell Anatomy 0.000 description 75
- 239000000047 product Substances 0.000 description 63
- 239000000463 material Substances 0.000 description 56
- 239000003814 drug Substances 0.000 description 47
- 210000003491 skin Anatomy 0.000 description 44
- 208000027418 Wounds and injury Diseases 0.000 description 36
- 206010052428 Wound Diseases 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 28
- -1 for example Substances 0.000 description 27
- 239000000835 fiber Substances 0.000 description 26
- 229940124597 therapeutic agent Drugs 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 229940127554 medical product Drugs 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 239000006185 dispersion Substances 0.000 description 20
- 210000003298 dental enamel Anatomy 0.000 description 19
- 230000006378 damage Effects 0.000 description 18
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 18
- 239000002994 raw material Substances 0.000 description 18
- 239000007788 liquid Substances 0.000 description 16
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 15
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 15
- 230000003796 beauty Effects 0.000 description 15
- 229940126864 fibroblast growth factor Drugs 0.000 description 15
- 239000002657 fibrous material Substances 0.000 description 15
- 210000004872 soft tissue Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 230000035882 stress Effects 0.000 description 15
- 102000013275 Somatomedins Human genes 0.000 description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000003925 fat Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 11
- 238000007385 chemical modification Methods 0.000 description 11
- 239000003102 growth factor Substances 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 230000011759 adipose tissue development Effects 0.000 description 10
- 206010061592 cardiac fibrillation Diseases 0.000 description 10
- 230000002600 fibrillogenic effect Effects 0.000 description 10
- 238000002513 implantation Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 210000000130 stem cell Anatomy 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000013270 controlled release Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 150000001450 anions Chemical class 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000017520 skin disease Diseases 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 229960003276 erythromycin Drugs 0.000 description 6
- 238000013265 extended release Methods 0.000 description 6
- 238000001879 gelation Methods 0.000 description 6
- 239000011121 hardwood Substances 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 206010072170 Skin wound Diseases 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 238000004879 turbidimetry Methods 0.000 description 5
- 238000009736 wetting Methods 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000005418 vegetable material Substances 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 235000018185 Betula X alpestris Nutrition 0.000 description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 229920001131 Pulp (paper) Polymers 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960002626 clarithromycin Drugs 0.000 description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 229960002383 halcinonide Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 210000004681 ovum Anatomy 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 229960000707 tobramycin Drugs 0.000 description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 2
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 102100031786 Adiponectin Human genes 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010020326 Caspofungin Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- CFHBWCDGXBGNDJ-UHFFFAOYSA-N N-(5-phenylpentylidene)hydroxylamine Chemical compound ON=CCCCCc1ccccc1 CFHBWCDGXBGNDJ-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- FCKLFGKATYPJPG-SSTBVEFVSA-N Oxendolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1C[C@H](CC)[C@H](O)[C@@]1(C)CC2 FCKLFGKATYPJPG-SSTBVEFVSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960002255 azelaic acid Drugs 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 2
- 229960000428 carbinoxamine Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 2
- 229960003034 caspofungin Drugs 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 150000001768 cations Chemical group 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- KDULJHFMZBRAHO-UHFFFAOYSA-N cioteronel Chemical compound C1C(=O)CC2C(CCCCC(CC)OC)CCC21 KDULJHFMZBRAHO-UHFFFAOYSA-N 0.000 description 2
- 229950000970 cioteronel Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- 229940060037 fluorine Drugs 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960001474 meclozine Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960003128 mupirocin Drugs 0.000 description 2
- 229930187697 mupirocin Natural products 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 229950006827 oxendolone Drugs 0.000 description 2
- 229960005244 oxymetholone Drugs 0.000 description 2
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 2
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229940041153 polymyxins Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960002847 prasterone Drugs 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229960005429 sertaconazole Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 229940114926 stearate Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 229960000580 terconazole Drugs 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 150000003625 trehaloses Chemical class 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 229960003223 tripelennamine Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- RDVXUHOSYIBGBT-ZWNOBZJWSA-N (2S,3R)-bifluranol Chemical compound C1([C@@H](C)[C@@H](CC)C=2C=C(F)C(O)=CC=2)=CC=C(O)C(F)=C1 RDVXUHOSYIBGBT-ZWNOBZJWSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- SSMSBSWKLKKXGG-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-isopropylaminoethanol Chemical compound CC(C)NCC(O)C1=CC=CC=C1Cl SSMSBSWKLKKXGG-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- KAWOEDMUUFFXAM-UHFFFAOYSA-N CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 Polymers CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 KAWOEDMUUFFXAM-UHFFFAOYSA-N 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010049047 Echinocandins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- KDYQVUUCWUPJGE-UHFFFAOYSA-N Ethamoxytriphetol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC=CC=1)CC1=CC=C(OC)C=C1 KDYQVUUCWUPJGE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- SIXHCCPAJIVTOY-UHFFFAOYSA-N Flutimide Natural products CC(C)CC1=NC(=CC(C)C)C(=O)N(O)C1=O SIXHCCPAJIVTOY-UHFFFAOYSA-N 0.000 description 1
- 229930195503 Fortimicin Natural products 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 description 1
- 240000008375 Hymenaea courbaril Species 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000034655 MIF Human genes 0.000 description 1
- 108060004872 MIF Proteins 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- WYZDXEKUWRCKOB-YDSAWKJFSA-N Mestanolone Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 WYZDXEKUWRCKOB-YDSAWKJFSA-N 0.000 description 1
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- ZXSWTMLNIIZPET-ZOFHRBRSSA-N Normethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 241000381142 Pachydermia Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 241000351396 Picea asperata Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- AZJUJOFIHHNCSV-KCQAQPDRSA-N Polygodial Polymers C[C@@]1([C@H](C(C=O)=CC2)C=O)[C@@H]2C(C)(C)CCC1 AZJUJOFIHHNCSV-KCQAQPDRSA-N 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000168036 Populus alba Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 241000159241 Toxicodendron Species 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- HFFLGKNGCAIQMO-UHFFFAOYSA-N Trichloroacetaldehyde Natural products ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
- 241000332824 Tsuga chinensis Species 0.000 description 1
- 235000010183 Tsuga mertensiana Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- KHRRLLSDLVLEIT-BKWLFHPQSA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] pyridine-3-carboxylate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)CC[C@@]21C)C(=O)C1=CC=CN=C1 KHRRLLSDLVLEIT-BKWLFHPQSA-N 0.000 description 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 description 1
- 229950006816 albaconazole Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000000576 arachnoid Anatomy 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- BIDUPMYXGFNAEJ-APGVDKLISA-N astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical group CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- FFIAPLNALYDYQK-UHFFFAOYSA-L barium(2+);[2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl phosphate Chemical compound [Ba+2].OCC1OC(O)(COP([O-])([O-])=O)C(O)C1O FFIAPLNALYDYQK-UHFFFAOYSA-L 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- LJWIAZFZRNWQOL-UHFFFAOYSA-N benzene;1,3-thiazole Chemical compound C1=CSC=N1.C1=CC=CC=C1 LJWIAZFZRNWQOL-UHFFFAOYSA-N 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229950004654 bifluranol Drugs 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229950007271 boldenone Drugs 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229950004783 cipionate Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229950011462 clorprenaline Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- ZGRKFKYTCMLCCF-UHFFFAOYSA-N cobalt;oxalonitrile Chemical compound [Co].N#CC#N ZGRKFKYTCMLCCF-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 108700001680 des-(1-3)- insulin-like growth factor 1 Proteins 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 1
- 229950010160 dimethocaine Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940099182 dramamine Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 208000012610 eosinophil disease Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001595 flow curve Methods 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- SIXHCCPAJIVTOY-UITAMQMPSA-N flutimide Chemical compound CC(C)CC1=N\C(=C/C(C)C)C(=O)N(O)C1=O SIXHCCPAJIVTOY-UITAMQMPSA-N 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical class [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Chemical class 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- 229940063647 marezine Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002660 mepivacaine hydrochloride Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 229950008604 mestanolone Drugs 0.000 description 1
- 229960005272 mesterolone Drugs 0.000 description 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960003377 metandienone Drugs 0.000 description 1
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960000270 methylestrenolone Drugs 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- HFMDLUQUEXNBOP-UHFFFAOYSA-N n-[4-amino-1-[[1-[[4-amino-1-oxo-1-[[6,9,18-tris(2-aminoethyl)-15-benzyl-3-(1-hydroxyethyl)-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl] Chemical compound OS(O)(=O)=O.N1C(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)CCCCC(C)CC)CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C1CC1=CC=CC=C1 HFMDLUQUEXNBOP-UHFFFAOYSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229950002088 nifungin Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000492 norethandrolone Drugs 0.000 description 1
- ZDHCJEIGTNNEMY-XGXHKTLJSA-N norethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 ZDHCJEIGTNNEMY-XGXHKTLJSA-N 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- 229960000464 oxandrolone Drugs 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- ZUBDXGHKAAMAAA-RFXJPFPRSA-N penmesterol Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)CC2)C)(O)C)C=C1C=C2OC1CCCC1 ZUBDXGHKAAMAAA-RFXJPFPRSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 229960001045 piperocaine Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- FPGPDEPMWUWLOV-UHFFFAOYSA-N polygodial Natural products CC1(C)CCCC2(C)C(C=O)C(=CC(O)C12)C=O FPGPDEPMWUWLOV-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- 229960005094 prilocaine hydrochloride Drugs 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 1
- 229950004154 ravuconazole Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- ZKMNUMMKYBVTFN-UHFFFAOYSA-N ropivacaine Chemical compound CCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-UHFFFAOYSA-N 0.000 description 1
- 229960001813 ropivacaine hydrochloride Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229950005137 saperconazole Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 229940029273 trichloroacetaldehyde Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000000214 vapour pressure osmometry Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/027—Fibers; Fibrils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
Abstract
This disclosure relates to the method that the acellular tissue extract in the hydrogel comprising nanometer fibril cellulose is dried, this method includes providing the hydrogel comprising nanometer fibril cellulose, acellular tissue extract comprising bioactive substance mixture is provided, polyethylene glycol is provided, trehalose is provided, hydrogel, acellular tissue extract, polyethylene glycol and trehalose are mixed to obtain mixture, and mixture is freeze-dried, to obtain acellular tissue extract in the dry hydrogel comprising nanometer fibril cellulose.This disclosure relates to comprising nanometer fibril cellulose, acellular tissue extract, polyethylene glycol and trehalose dried hydrogel, the acellular tissue extract includes the mixture of bioactive substance, wherein, the water content of dried hydrogel is 10% (w/w) or lower.
Description
Technical field
This disclosure relates to the hydrogel comprising nanometer fibril cellulose, the nanometer fibril cellulose includes acellular tissue
Extract can be used as medical product in medical application;And it is related to being used to prepare and dry this and contains acellular tissue
The method of the hydrogel of extract.Medical application includes by bioactive agent delivery to target tissue.
Background
Nanometer fibril cellulose refers to the cellulose fibril or fibril beam of the separation obtained in the cellulosic material.Nanometer is former
Fine cellulose is based on natural polymer abundant in nature.Nanometer fibril cellulose has forms cohesive hydrogel in water
Ability.
Nanometer fibril cellulose production technology is the grinding of the water-borne dispersions based on pulp fiber.Nanometer fibril cellulose
Concentration in dispersions is usually extremely low, generally about 0.3-5%.After grinding or Homogenization, obtained nanometer fibril is fine
Tieing up cellulosic material is diluted viscoplasticity hydrogel of dilution.
Due to its nanoscale structures, nanometer fibril cellulose has unique property, can be realized conventional fibre element not
The function that can be provided.However, nanometer fibril cellulose is also a kind of challenging material due to identical.For example, receiving
Rice fibril cellulose is likely difficult to be dehydrated or be handled.In addition, after dewatering, being generally difficult to the material rehydration so that dry
Or gelation (regel) again, to obtain the material having with the original nanometer fibril cellulose same nature before dehydration or drying.
Particularly challenging dehydration is freeze-drying.
Summary of the invention
One embodiment is provided to the acellular tissue extract in the hydrogel comprising nanometer fibril cellulose
The method being dried, which comprises
Hydrogel comprising nanometer fibril cellulose is provided,
Acellular tissue extract comprising bioactive substance mixture is provided,
Polyethylene glycol is provided,
Trehalose is provided,
Hydrogel, acellular tissue extract, polyethylene glycol and trehalose are mixed to obtain mixture, and
Mixture is freeze-dried to obtain the drying in the dry hydrogel comprising nanometer fibril cellulose
Acellular tissue extract.
One embodiment offer the method includes nanometer fibril cellulose, acellular tissue extract, poly- second
The hydrogel of the drying of two pure and mild trehaloses, the acellular tissue extract include the mixture of bioactive substance.
It includes nanometer fibril cellulose, acellular tissue extract, polyethylene glycol and trehalose that one embodiment, which provides,
Dried hydrogel, the acellular tissue extract includes the mixture of bioactive substance, wherein the water content of hydrogel
For 10% (w/w) or lower, such as 2-10% (w/w).
Main embodiment is disclosed in independent claims.Various embodiments are in the dependent claims
It is open.Unless otherwise indicated, embodiments and examples described in dependent claims free of one another can combine.
It is surprisingly found that dry when carrying out freezing to acellular tissue extract in nanometer fibril cellulose aquagel
Polyethylene glycol and trehalose are applied in combination in dry process as cryoprotector, dry product, the drying can be obtained
Product can rehydration or redisperse at the primitiveness for restoring tissue extract in the hydrogel comprising nanometer fibril cellulose
The form of matter, that is, dry product can carry out gelation again.The property includes gelling properties and acellular tissue extract
Activity, can be further from hydrogel controlled release.(it contains poly- second two to freeze-drying hydrogel containing nanometer fibril cellulose
Pure and mild trehalose) gel chemical conversion and similar homogeneous hydrogel before freeze-drying again, meanwhile, only contain polyethylene glycol or seaweed
Gel is melted into paste and granular form to a kind of similar freeze-drying hydrogel again in sugar.Selected cryoprotector
In the presence of the curve that will not influence bioactivator and discharged from gel.By the way that hydrogel is dried, medical product can be obtained
The very long shelf-life.In particular, containing unstable activating agent in humid conditions (for example, to the sensitive reagent of hydrolysis and
Protein) gel can successfully be freeze-dried into be substantially free of water or it is practical not aqueous and therefore have extended stability and
The form of shelf-life.The freeze-drying medical product can even store at room temperature, and can pass through addition before use
Liquid (for example, water or salt water) carries out gelation again.In addition, the combination of polyethylene glycol and trehalose prevents a nanometer fibril cellulose
It precipitates or deposits in solution or dispersion, which cannot obtain separately through one of cryoprotector.
It has also been found that the hydrogel containing nanometer fibril cellulose may be used as providing the material of various different molecular controlled releases
Material, for example, it may be used as active therapeutic agent or enamel.Nanometer fibril cellulose aquagel is capable of providing the extension of activating agent
Release, the effect can be applied to various medical treatment and beautifying use.In various hydrogel concentrations and various different sizes and type
Releasable molecule in obtain the effect.
Certain favorable properties of hydrogel comprising nanometer fibril cellulose include flexible, elasticity and remoldability.Due to
Hydrogel contains a large amount of water, can also show good permeability.For example, when hydrogel is used as the covering of reparation wound
Or when being used for other medical applications, such as when for delivering therapeutic agents or enamel, these properties are useful.
Flexibility is the feature needed in many applications, such as in medical application.For example, including nanometer fibril cellulose water
The flexible patch and dressing of gel can be used for administering on skin, such as covering wound and other damages or injury, such as
It burns.
The hydrogel of some embodiments also provides high water holding capacity and molecular diffusion rates property, these performances are in medicine
Using etc. be desired in (such as wound healing).Big hydrogel can be prepared and/or be shaped, can be used for covering large area.
Hydrogel as described herein can be used for medical application comprising nanometer fibril cellulose material and living tissue
Contact.It was found that nanometer fibril cellulose provides uncommon property when being for example administered on skin or being administered on damage field
Matter.The product comprising nanometer fibril cellulose is compatible with living tissue high biological as described herein and provides several advantageous effects
Fruit.Without being bound by any specific theoretical constraint, it is believed that the hydrogel containing extremely hydrophilic nanometer fibril cellulose has very
High specific surface area, and therefore have high water holding capacity, when being applied to skin or other tissues, tissue or wound and comprising
Advantageous wet environment is formed between the hydrogel of nanometer fibril cellulose.A large amount of free hydroxyl groups in nanometer fibril cellulose exist
Hydrogen bond is formed between nanometer fibril cellulose and hydrone, and realizes nanometer high water holding capacity of fibril cellulose and gel shape
At.Because of a large amount of water in nanometer fibril cellulose aquagel, it is believed that only water is contacted with tissue, and may be implemented liquid and/
Or reagent moves to hydrogel from skin or wound or moves to skin or wound from hydrogel.
When being used to cover wound or other damages or injury for hydrogel, such as such product or other products
Part (for example, part of plaster, dressing, Medical paster or plaster, patch or dressing), provide multi-effect.Product
Availability is fine, is damaged because the product easily can be applied and be removed without, such as tear.When for covering wound
When, hydrogel protects the wound from infection, and keeps wet environment so that wound healing.Hydrogel will not be as traditional material
It is attached on impaired skin or wound in an irreversible fashion like that, the traditional material is generally difficult to do not damaging healing area
It is removed in the case where domain.Condition between product and skin facilitates the healing of damage field.
The medical aquogel of some embodiments treatment damage skin (wherein, skin may it is impaired in variable depth or
Possibly even lose skin) when or be particularly advantageous in the treatment of graft (such as skin graft).Hydrogel can
To be used for, covering damages or transplants object area and it is used as protective layer.
Hydrogel can be also used for controllably and effectively discharging and delivering to object (for example, patient or user) biological living
Property agent, such as include the reagent in acellular tissue extract, such as by transdermal route or by other approach, such as directly
It connects delivering or is discharged into impaired subcutaneous area.Controlled release refers to for example obtains required one or more reagents whithin a period of time
Rate of release and/or distribution, this may be influenced by following factor: gel selection, such as the percentage or gel of gel
Thickness, the concentration or form of releasable agent, the presence of any auxiliary agent, or have to the rate of release and/or activity of releasable agent
The other conditions of influence, such as pH, temperature etc..As previously mentioned, specified conditions and release characteristics between tissue and hydrogel
Combined effect provides effective delivering of the substance into living tissue.Nanometer fibril cellulose aquagel provides hydrophilic matrix,
It is nontoxic, biocompatible, and is also biodegradable.For example, matrix can be by enzymatic degradation.On the other hand, water-setting
Glue is stable in physiological conditions.
For example, acellular tissue extract (especially adipose tissue extract) disclosed herein can be used for soft tissue work
Journey transformation.Soft tissue engineering, which is transformed, seeks to manufacture the replacement component of the soft tissue defect as caused by such as wound, for example, burn and
Scar, operation excision or congenital abnormality.In addition, the use (for example, filling of facial wrinkles) of beauty is recombination soft tissue
Important application.Particularly preferred therapeutic targets are fatty sub-dermal soft tissues, also referred to as hypodermis (hypodermis), subcutaneous group
It knits, hypodermal layer (subcutis) or fascia superficialis, is vertebrate by the lowest level of dermal system.At with adipose tissue extract
When managing subcutaneous tissue, the bioactive substance of extract can promote the regeneration of sub-dermal soft tissue and skin.
Detailed description of the invention
Present disclose provides the hydrogels containing nanometer fibril cellulose, are alternatively referred to as nanometer fibril cellulose water-setting
Glue.Hydrogel can be used as product offer, can also contain other substances or other elements, such as reinforcing material, covering material
Material, activating agent, salt etc..Hydrogel can also be used as medical aquogel or medical product provides, or be medical aquogel or doctor
Treat product.
More specifically, this application discloses in the hydrogel containing nanometer fibril cellulose, polyethylene glycol and trehalose
Acellular tissue extract, the acellular tissue extract includes the mixture of bioactive substance.
This application discloses a kind of medical aquogel, contain nanometer fibril cellulose and acellular tissue extract, institute
State the mixture that acellular tissue extract includes bioactive substance.The hydrogel can be used for freezing described herein
Bioactive substance is given to object, such as patient in the case where protective agent or no cryoprotector described herein.
Term " medical treatment " refers to that product or in which product (that is, product of the hydrogel containing embodiment) are used for or fit
Purposes for medical purpose.Medical product can be sterilized or it can sterilize, for example, by using temperature, pressure,
Humidity, chemical substance, radiation or combinations thereof sterilize.Product can such as HIGH PRESSURE TREATMENT, or other utilization can be used
The method of high temperature is handled, and in this case, product should be resistant to the high temperature more than 100 DEG C, and for example, at least 121 DEG C or 134 DEG C
High temperature.In an example, product high pressure sterilization 15 minutes at 121 DEG C.The Temperature Treatment should be preferentially by any life
Object activating agent carries out before being added to product, to avoid bioactivator denaturation.It also wants to medical product and is free of pyrogen, and it
Without containing undesirable protein residues etc..Medical product is preferably to target non-toxic.Ultraviolet sterilization can also be used.Medical treatment produces
Product are readily applicable to such as cosmetic purpose.
Nanometer fibril cellulose (NFC) hydrogel (for example, anion N FC hydrogel) of some embodiments can with when
Between function the controlled release of active agents, it is especially particularly true when temperature and pH constant.It was found that NFC hydrogel can use specific figuration
Agent freeze-drying simultaneously still can gelatine again.It is experimentally confirmed that the freeze-drying of NFC hydrogel actually to non-frozen drying sample and
Release profiles between freeze drying example and again gelation sample do not influence, and are identical.The result shows that: by PEG and
Trehalose together as cryoprotector freeze-drying method actually to NFC hydrogel (such as anionic hydrogel) used
Releasability do not influence.Anionic hydrogel is preferred for many applications.For example, different from other ranks, yin from
The modified nanometer fibril cellulose of son is not easy to precipitate.Anion (aniconic) rank is also particularly suitable the certain activity of release
Agent.
In this specification, unless otherwise specified, percentage values are based on weight (w/w).If provided any
Numberical range, then the range includes the upper limit value provided and lower limit value.
One embodiment provide in the hydrogel containing nanometer fibril cellulose, polyethylene glycol and trehalose can
The acellular tissue extract of freeze-drying, the acellular tissue extract include the mixture of bioactive substance.Poly- second
Two pure and mild trehaloses are used as cryoprotector to provide synergistic effect, and nanometer fibril hydrogel is allowed to carry out in this way
Freeze-drying, with the lyophilisation product of the essentially identical property of hydrogel before obtaining and being freeze-dried.When the poly- second of exclusive use
When glycol or trehalose, they do not show antifreezing effect significant so, may indicate that it as nanometer fibril cellulose
The cryoprotector of hydrogel is effective, such as prevents a nanometer fibril Cellulose precipitates.In one example, by hydrogel
Gross mass calculate, the hydrogel that can be freeze-dried include 0.1-2% (w/w) polyethylene glycol and 0.05-1.0 (w/w) sea
Algae sugar.In one embodiment, acellular tissue extract is adipose tissue extract, for example, human fat tissue extract.
One embodiment, which provides, extracts acellular tissue dry in the hydrogel comprising nanometer fibril cellulose
The method of object, which comprises
Hydrogel comprising nanometer fibril cellulose is provided,
Acellular tissue extract comprising bioactive substance mixture is provided,
Polyethylene glycol is provided,
Trehalose is provided,
Hydrogel, acellular tissue extract, polyethylene glycol and trehalose are mixed to obtain mixture, and
Mixture is freeze-dried thin to obtain the nothing in the dry hydrogel comprising nanometer fibril cellulose
Born of the same parents' tissue extract.
One embodiment provides a kind of medical aquogel, contains nanometer fibril cellulose and acellular tissue extracts
Object, the acellular tissue extract include the mixture of bioactive substance.One embodiment provides a kind of medical water
Gel contains nanometer fibril cellulose and acellular tissue extract and another or a variety of therapeutic agents or beauty
Agent, the acellular tissue extract include the mixture of bioactive substance.Medical aquogel is for giving substance or reagent
Give object.Medical aquogel can also include other ingredients, for example, polyethylene glycol and trehalose as described herein.Object can
To be patient or any other object for needing reagent, such as mankind or animal.
Acellular tissue extract
Tissue extract is merged with the hydrogel comprising nanometer fibril cellulose.The tissue extract be it is cell-free or
Person is acellular, these terms can be used interchangeably.Acellular tissue extract includes the mixture of biological substance, meaning
Tissue extract comprise more than a type of bioactive substance, be referred to as bioactivator.Biological active matter
Matter can be protein, hormone, the factor, such as growth factor, differentiation factor or any other bioactie agent or it is any its
Its bioactive substance or molecule.Bioactive substance can also include extracellular component, that is, be present in the group of extracellular space
Point, such as protein and non-proteinaceous matter, such as DNA, RNA or lipid;Or extracellular fibril, such as collagen, elasticity
Albumen, proteoglycan, or the extracellular vesica containing biological activity protein or nucleic acid, such as microcapsule bubble or other vesicas.It is raw
Active substances are obtained by source cell, and the derived cell can derive from tissue or cell culture.Bioactive substance or
Bioactivator or bioactive compound are on living organism, tissue or the influential substance of cell.Acellular tissue extracts
Object does not refer to the protein being separately separated or other molecules, and refers to the one group of substance obtained together from source cell, can be
One seed type or more than a seed type.Acellular tissue extract comprising bioactive substance mixture herein can also be with
Referred to as acellular tissue extract.
Tissue used herein refers to any animal or plant tissue.In one embodiment, tissue is animal groups
It knits, for example, people organizes.The tissue can be soft tissue comprising connection, support or the group for surrounding body other structures and organ
It knits.In one example, tissue does not include sclerous tissues, such as bone.The example of soft tissue include tendon, ligament, fascia, skin,
Fibr tissue, adipose tissue and synovial membrane (it is connective tissue) and muscle, nerve and blood vessel (it is not connective tissue).Herein
Tissue used further includes blood and other celliferous fluids of packet, for example, body fluid and cell culture medium.
Tissue can be obtained from the body of animal or people.Acellular tissue extract can be obtained from small tissue blocks or living cells
?.In one embodiment, acellular tissue extract is obtained from tissue, for example, living cells, that is, the cell to live
(living cell), the tissue are directly obtained by body, for example, the sample or tissue isolate that obtain from body, that is, thin
Born of the same parents and without culture.Small tissue blocks refer to the tissue that origin source (for example, body) obtains, and it has been cut into block but possibility
It is not homogenised.Acellular tissue extract is the solution obtained from source cell, such as by making cell rupture and removing all
The solution that particulate matter obtains, or do not make cell rupture and being incubated for living cells in the solution or homogenize and recycled from solution
Extract and the solution obtained.Solution can be aqueous solution, such as saline solution, buffer solution or cell culture medium.When thin
When born of the same parents do not rupture or homogenize, the substance and extracellular substances of secretion are only extracted, so as to cause more limited amount in extract
Different material.In one example, acellular tissue extract (especially adipose tissue extract) is obtained by lipsuction from body
?.It is the specific example of homogeneous pattern tissue isolate by the tissue that lipsuction obtains, wherein cell is not ruptured or collapsed substantially
Solution, but at least partly, preferably most cells are living.Cell (such as the biopsy, liposuction obtained from the tissue of removal
Art etc.) extracellular component can be contained.
In one embodiment, acellular tissue extract is obtained by the cell through cultivating, for example, in conditioned medium
The cell of middle culture.One or more conditioned mediums are the culture mediums used by cellular portions, such as wherein cell passes through
Cross the culture medium of a few hours or a couple of days culture.Although some components exhaust, it is rich in cell-derived material, such as a small amount of thin
Intracellular cytokine, growth factor etc..The cell conditioned medium, and can be with one by with the growth of much lower density sertoli cell
A little fresh culture mixing.In this case, acellular tissue extract can be conditioned medium or it can come from item
Part culture medium.
In general, tissue extract can be filtered after recycling from cell.This can be ended in this way by using having
The filter of value carries out, enable to the solution with bioactive substance by but prevent cell or cell fragment logical
Cross filter.Ensure not celliferous another option is that being centrifuged to extract and recycling supernatant in extract.
Source cell can be protokaryon or eukaryotic.For example, may include microbial cell, such as bacterial cell or yeast
Cell.Eukaryocyte can be plant cell or zooblast.The cell is preferably zooblast, more preferably people's cell.Carefully
The example of born of the same parents includes: stem cell, neoblast, precursor and the cell broken up completely and their combination.Eukaryon is thin
The example of born of the same parents includes: portable cell, for example, stem cell, for example, omnipotent (omnipotent) cell, pluripotency
(pluripotent) cell, multipotency (multipotent) cell, few energy (oligopotent) cell or single energy
(unipotent) cell.In the case where human embryo stem cell, cell can come from the cell line of deposition or by unfertilized ovum
[i.e. " parthenote (parthenote) " ovum] is made, or the ovum from single-female generation activation, so that Human embryo will not be destroyed.
In some instances, cell includes cell type selected from the group below: keratocyte, keratinocyte, fibroblast, epithelial cell
And their combination.In some instances, cell is selected from the group: stem cell, progenitor cells, precursor, phoirocyte, on
Chrotoplast, nerve cell, endothelial cell, fibroblast, keratinocyte, smooth muscle cell, stroma cell, fills at myocyte
Cell plastid, immune system cell, hematopoietic cell, dendritic cells, hair follicle cell and their combination.
In one embodiment, acellular tissue extract is not to be obtained from the cell through cultivating.Cell table through cultivating
Reveal the source cell type different from the tissue cell obtained by directly obtaining from body, and its can have it is different most
Whole purposes.
In one embodiment, acellular tissue extract is adipose tissue extract, for example, human fat tissue extracts
Object.Product containing adipose tissue extract can be used for providing the microenvironment for being suitable for cell Proliferation and differentiation, therefore lead to shape
It is transplanted at adipose tissue without exogenous cells.Optimal microenvironment mentions fat stem cell from the migration of surrounding tissue
Height, and Cell differentiation inducing activity is at mature fat cell.Developmental tissue needs neovascularization to avoid transplanting tissue
Necrosis, scar are formed and are reabsorbed, and secrete a variety of differentiation factors.
One embodiment provides cell-free adipose tissue extract, preferably with predetermined amount include at least VEGF,
FGF-2 and IGF-1.Cell-free adipose tissue extract can be further containing one or more other bioactive substances or sheet
Other materials disclosed in text.In one embodiment, extract includes at least: every 1mg gross protein, at least VEGF of 1pg,
At least IGF-1 of the FGF-2 of 70pg and at least 50pg.In one embodiment, the VEGF content of every 1mg gross protein
It is at least 7pg.The extract can be used for the induction of the vascularization in soft tissue repair or engineered and tissue engineer,
Such as wound healing, treatment burn and treatment ischemic conditions.One specific example of the purposes is that treatment sub-dermal soft tissue lacks
It loses.
One example is to provide the side for being used to prepare acellular tissue extract (for example, cell-free adipose tissue extract)
Method.Method includes the following steps: the Heterogenization tissue sample containing living cells a) is provided, for example, adipose tissue sample, b)
Extract is collected or recycled in the solution from solution by the sample incubation predetermined time and c), or collects or recycles
Solution is as extract.The method can also include the cell for first washing or removing in other ways rupture or homogenize, with
It provides only comprising living cells or the main sample comprising living cells.The method can also include: to carry out final mistake to extract
Filter from extract to remove any remaining cell.Another example provides the acellular tissue obtained by the method and extracts
Object, for example, cell-free adipose tissue extract.For example, the predetermined time can be 5 minutes to 48 hours, such as 1-24 hour,
0.5-2 hour, 1-2 hour, 0.5-6 hour, 0.5-12 hour, 1-12 hour, 2-12 hours or 12-24 hours, for example, about 1 is small
When, about 2 hours, about 24 hours or about 48 hours.
Adipose tissue includes that fat cell, endothelial cell, fibroblast, pericyte and the fat of various differentiation states are dry
Cell and the mescenchymal stem cell that multiple cell lineages can be divided into.From the beginning fat forms (that is, forming new fats tissue)
It is promising soft tissue engineering remodeling method.The use of adipose tissue is based on following research: offer being provided and is increased suitable for cell
Thus the microenvironment grown and broken up results in blood vessel and adipose tissue and transplants without exogenous cells.Optimal microenvironment
So that fat stem cell is improved from the migration of surrounding tissue, and inducing endothelial cell and Preadipocyte are divided into mature rouge
Fat cell, loose connective tissue and myocyte and vascular cell.It is developmental tissue always need neovascularization to avoid
Necrosis and scar are formed, that is, functional maturation adipose tissue is developed.
Cell-free adipose tissue extract (ATE) as described herein has inducing adipose tissue and blood vessel fast in medicine-feeding part
Speed forms the potentiality without giving cell.ATE can from the beginning be formed for fat and vascularization generates best microenvironment, and
Therefore it can be used for soft tissue repair and/or engineered.
The term as used herein " adipose tissue extract " (ATE) refers to the biological active matter secreted by fat tissue cell
Matter, preferred fat is formed and angiogenesis factor, that is, the adipose tissues of different differentiation states, endothelial cell, fibroblast,
Pericyte and fat stem cell.Adipose tissue extract is different from traditional conditioned medium, for example, extract is from group
Knit what block or living cells were collected.The preparation process of ATE does not include cell culture, and extract obtained is concentrated than conditioned medium
Much, and incubation time is short, differs from a few minutes to several days.
Adipose tissue extract can be by fat or the adipose tissue sample system obtained by such as lipsuction or surgical operation
At.If desired, tissue sample is cut into small pieces, so that cell keeps work substantially.Lipsuction material can directly be used.Change speech
It, the processing of tissue sample does not include homogenizing.By in the medium, in aseptic salt solution, in phosphate buffered saline (PBS)
In or other suitable isotonic aqueous buffers in incubated cell extract bioactie agent, wherein in incubation period cell
Or bioactie agent is discharged into liquid phase by tissue block.Then ATE is collected, that is, the not liquid phase of cell.ATE can also be
It is filtered before use to be sterilized and be ensured that extract is cell free fluid to extract.Obtained ATE is comprising egg
The cell-free mixture of white matter (for example, cell factor) and other bioactive substances.
Not only self but also allogeneic adipose tissue may be used as the source of ATE, and can be handled with
It completes as described above.Since extract is cell-free, even if in the allogeneic that identical extract is used for multiple patients
Also immune response and allergic reaction are unlikely to occur in use.The support of this zooscopy previously carried out, wherein planting
The people ATE (xenograft) for entering rat will not cause any inflammatory reaction or other complication.
ATE is the optimum cell factor cocktails of the Adipogenesis and angiogenesis factor by fat tissue cell's expression.
The bioactive substance of ATE can be measured by conventional method as known in the art (such as ELISA).In research before
In, the expression of 120 kinds of cell factors in various ATE is measured.Longer incubation time (such as at 24 hours or longer
Between) more vascularization extracts are generated, and the incubation time of short incubation time and length all generates Adipogenesis mixture.
ATE adjustable is thin comprising required or predetermined amount Adipogenesis and angiogenesis factor, including blood vessel endothelium
The intracellular growth factor (VEGF), Basic fibroblast growth factor (FGF-2) and insulin-like growth factor (IGF-1).It is required
The composition wanted can depend on desired use.According to current knowledge, VEGF and FGF-2 are considered as stimulation vascularization
Important factor, and FGF-2 and IGF is critically important for stimulation Adipogenesis.Therefore, in one embodiment, ATE is at least wrapped
Contain: every 1mg gross protein, at least IGF-1 of the FGF-2 of the VEGF of 1pg, at least 70pg and at least 50pg.The ATE is special
Suitable for for example in soft tissue repair and engineered moderate stimulation Adipogenesis.In another embodiment, ATE is at least wrapped
Contain: every 1mg gross protein, at least IGF-1 of the FGF-2 of the VEGF of 7pg, at least 70pg and at least 50pg.Such ATE is special
Angiogenesis Yong Yu not be stimulated, such as heals and is handled in ischemic conditions and burn for stimulating blood vessel raw in inducing wound
At.The ATE of different adjustment can also contain different amounts of a variety of other cell factors, although it may be not for specific application
It is always vital.In general, ATE should include the IGF-1 and FGF-2 and about 1:100 to about 1:10 of about 2:1 to about 1:2
VEGF and FGF-2.
It can be by adjusting containing for adipose tissue extract using different incubation time and temperature in the preparation of ATE
Amount.In general, the range of incubation time is a few minutes to a few hours, for example, overnight.For example, about 1 hour incubation time usually obtains
The total protein content of 1.7-2.5mg/ml, the IGF-1 content of 200-1300pg/ml are obtained, the FGF-2 of 200-1400pg/ml contains
The VEGF content of amount and 2-25pg/ml.In other words, 1 hour incubation time usually obtains every 150-550pg of 1mg gross protein
IGF-1 content, the VEGF content of the FGF-2 content of every 1mg gross protein 100-500pg and every 1mg gross protein 3-20pg.
The extract of the type is Adipogenesis and vascularization.However, if needing extra high VEGF concentration in extract
(200-1400pg/ml, the VEGF of every 25-500pg of 1mg protein), for example, the induction of vascular shape especially in required target tissue
At incubation time should extend to for example, about 24 hours.24 hours incubation times usually obtain every 1mg gross protein 60-
The IGF-1 content of 200pg, the FGF-2 content of every 1mg gross protein 130-500pg and every 1mg gross protein 25-500pg's
VEGF content.In addition, various incubation temperatures (usually room temperature is to about 37 DEG C) can be used for changing adipose tissue extract.However
In some embodiments, lower temperature, such as 4 DEG C can be used.In other embodiments, higher temperature can be used
Degree, as long as protein will not be denaturalized.
More generally, in extract VEGF concentration range be 1-1400pg/ml, preferably 10-1000pg/ml, more preferably
7-700pg/ml, most preferably 10-100pg/ml.In extract the concentration range of FGF-2 be 20-1500pg/ml, preferably 100-
1300pg/ml, more preferable 150-1000pg/ml, most preferably 200-800pg/ml.The concentration range of IGF-1 is in extract
100-1500pg/ml, preferably 150-800pg/ml, most preferably 200-500pg/ml.On the other hand, the gross protein of extract is dense
Degree range can be 0.75-3.5mg/ml.Total protein concentration ranges preferably from 1.4-2.7mg/ml, more preferable 1.8-2.7mg/
Ml, more preferable 2-2.7mg/ml, most preferably 2.1-2.5mg/ml.
The concentration of bioactive substance can also be limited relative to the total protein concentration of extract in extract.Cause
This, the amount (growth factor content of every 1mg protein) of VEGF may range from 1- in the extract containing 1mg gross protein
800pg, preferably 3.5-500pg, more preferable 7-300pg, most preferably 20-100pg.In extract containing 1mg gross protein
The amount (growth factor content of every 1mg protein) of FGF-2 may range from 1-1200pg, preferably 1-600pg, more preferable 70-
500pg, even more preferably 110-450pg, most preferably 250-350pg.(growth factor of every 1mg protein contains the amount of IGF-1
Amount) it may range from 50-700pg, preferably 100-500pg, more preferable 100-300pg, most preferably 110-230pg.
ATE also may include natively or be added thereto with further adjust a variety of other bioactive substances of ATE or its
Its substance, such as the Adipogenesis factor and angiogenesis factor, such as growth factor, interleukin, complement system product, sugared cortex
Hormone, prostaglandin, lipoprotein and free fatty acid and extracellular matrix components, such as collagen I, collagen IV
With collagen VI, proteoglycans, elastin laminin, microcapsule bubble of the vesica such as containing regulatory protein, peptide and/or nucleic acid, Yi Jitou
Bright matter acid.In addition, for example, ATE can use any desired other medicines of preceding supplement or medicament.It can reside in ATE
Substance example include: angiogenin, adiponectin, TIMP-1 and TIMP-2, MIF, IGFBP-6, NAP-2, thin voxel,
PDGF-BB, GRO, IL-6, MCP-1, thin voxel, CCL5 and VEGF.
It on the other hand, can be by further being adjusted using preceding removal substance (such as single growth factor or cell factor)
Save ATE.For example, if ATE is formed for main induction of vascular, such as processing ischemic conditions, angiogenesis suppression can be removed
Preparation (such as TIMP-1 and TIMP-2) and the main Adipogenesis factor (such as IGF-1, adiponectin and/or thin voxel).
The method of substance needed for this field is easy to get removal or separates, including growth factor is separated by immuno absorbence.
ATE is adjusted and may further include concentration (such as passing through centrifugation) or dilution (such as with culture medium, sterile
Saline or any other buffering isotonic solution) to obtain the suitable ATE for being used for special-purpose.
In some instances, the ATE for including in hydrogel as described herein may be used as cell culture medium or cell training
Base supplement is supported to study Adipogenesis or vascularization in vitro.ATE leads to the fat cell of differentiation in cell culture
It is uniformly distributed, it thus provides the excellent adipogenic cell model for reflecting situation in human body.So far, not yet
The cell model of suitable Adipogenesis differentiation.One example provides the method formed for induced lipolysis and induction of vascular
The method of formation.The method includes providing hydrogel or medical product described herein to patient with this need.
Overall goal is to substitute foreign sera in cell culture, particularly in clinical application.Human serum is very expensive,
It therefore is not best solution.In some instances, ATE can be used as cell culture constituents in cell culture medium or serum replaces
For object.This is not only at low cost, but also can be used for generating people's construct of tissue engineer, especially when the component of animal derived
It is particularly true when being not suitable for.
The content of tissue extract (for example, adipose tissue extract) can change in hydrogel.Tissue extract content
It can be expressed as protein content, some non-proteinaceous matters can also be contained even if tissue extract.In general, hydrogel can be with
Protein comprising 300 μ g/ml-1.2mg/ml, preferably 600 μ g/ml-1mg/ml, more preferable 800-900 μ g/ml.
When preparing the hydrogel containing cell-free extract, primary raw material includes nanometer fibril cellulose, and it includes straight
Cellulose fibril of the diameter in sub-micrometer range is made of cellulose fibril of the diameter in sub-micrometer range.Even if the material
It is also formed from the hydrogel network of assembling at low concentrations.The gel of these nanometer of fibril cellulose itself has high shear desaturation
Property and pseudoplastic behavior.
Nanometer fibril cellulose
Nanometer fibril cellulose is usually prepared by the cellulosic material of plant origin.Raw material can be based on cellulose-containing
Meaning vegetable material.Raw material may originate from certain bacterial fermentation processes.In one embodiment, vegetable material is timber.Wood
Material can come from softwood trees such as dragon spruce, pine tree, fir, larch, pesudotsuga taxifolia or Chinese hemlock spruce, or from palohierror for example birch, white poplar,
Poplar, alder, eucalyptus, Oak Tree, beech or locust tree, or the mixture from cork and hardwood.In one embodiment,
Nanometer fibril cellulose is obtained from wood pulp.In one embodiment, nanometer fibril cellulose is obtained from hard wood pulp.In a reality
In example, hardwood is birch.In one embodiment, nanometer fibril cellulose is obtained from soft wood pulp.
Nanometer fibril cellulose is preferably prepared by vegetable material.In an example, fibril is from non-thin-walled (non-
Parenchymal) vegetable material obtains.In this case, fibril can be obtained from secondary cell wall.This cellulose is former
A kind of fine abundant source is wood-fibred.Nanometer fibril cellulose is by homogenizing to the fibrous raw material from timber
It is made, the fibrous raw material can be chemical sizwe.It is disintegrated cellulose fibre to generate the fibril that diameter is only several nanometers,
Diameter is up to 50 nanometers, for example, 1-50 μm, and obtain fibrillar dispersion body in water.The size of fibril can reduce
The diameter of most of fibril is only in the range of 2-20 nanometers.It is essentially crystal from the fibril of secondary cell wall, is crystallized
Degree is at least 55%.This fibril can have the property different from the fibril of primary cell wall is originated from, for example originating from secondary thin
The dehydration of the fibril of cell wall may have more challenge.
As used herein, term " nanometer fibril cellulose " refers to the cellulose separated from the fibrous raw material based on cellulose
Fibril or fibril beam.These fibrils have the feature of high aspect ratio (length/diameter): their length can be more than 1 μm, and diameter
Generally remain less than 200nm.The smallest fibril is in the rank of so-called elementary fibril, and diameter is generally 2 to 12nm.Fibril
Scale and size distribution depend on refining methd and efficiency.Nanometer fibril cellulose may be characterized as the material based on cellulose,
The median length of middle particle (fibril or fibril beam) is no more than 50 μm, such as in the range of 1 to 50 μm, and particle diameter is small
In 1 μm, suitable range is 2 to 500nm.In the case where natural nano fibril cellulose, fibril in one embodiment
Average diameter in the range of 5 to 100nm, such as in the range of 10 to 50nm.The feature of nanometer fibril cellulose is big
The ability of specific surface area and strong formation hydrogen bond.In aqueous dispersion, nanometer fibril cellulose is generally rendered as light color or muddy
Gel-like material.According to fibrous raw material, nanometer fibril cellulose contains a small amount of other wood components, such as hemicellulose
Or lignin.The amount depends on plant origin.The common alias of nanometer fibril cellulose includes nanofibrillated cellulose (NFC)
And nano-cellulose.
The nanometer fibril cellulose of different stage can be based on the classification of three key properties: the distribution of (i) size, length and straight
Diameter, (ii) chemical composition, and (iii) rheological equationm of state.A rank is fully described, these properties can be used parallel.It is different
The example of rank include natural (or unmodified) NFC, oxidation NFC (high viscosity), oxidation NFC (low viscosity), carboxy methylation NFC and
Be cationized NFC.In these Major grades, it is other that there is also substates, such as: splendid fibrillation is compared to moderate fibrillation, height
Degree replaces compared to minuent substitution, low viscosity compared to high viscosity, etc..Fibrillation technology and the pre- modification of chemistry are to fibrillar size
Distribution has an impact.In general, nonionic rank has broader fibril diameter (such as 10-100nm or 10-50nm), and chemistry changes
Property rank then will carefully very much (such as 2-20nm).The distribution of modified rank is also narrower.Certain modifications (especially TEMPO- oxidation)
Shorter fibril can be generated.
According to raw material sources difference, such as hardwood (HW) and cork (SW) slurry, in final nanometer fibril cellulose products
There are different polysaccharide compositions.In general, preparing nonionic rank from the birch slurry of bleaching, the dimethylbenzene of high-content can be generated
(25 weight %).Modified rank is prepared from HW or SW slurry.These be modified ranks in, hemicellulose together with fiber prime field by
It is modified.Most probable, which is non-uniform, that is, some parts are higher compared to other parts modification degree.Therefore, can not
Can be carried out detailed chemical analysis --- modified product is usually the complex mixture of different polysaccharide structures.
In aqueous environments, cellulose nano-fibrous dispersion forms viscoplasticity hydrogel of dilution network.The gel is by dispersing
It is formed at relative lower concentration (such as 0.05 to 0.2% (w/w)) with the entanglement fibril of hydration.The viscoplasticity of NFC hydrogel can
It is characterized with such as dynamic vibration rheology measurement.
Nanometer fibril cellulose aquagel shows the distinctive rheological equationm of state.For example, nanometer fibril cellulose aquagel is
Shear thinning or pseudoplastic material, it means that its viscosity depends on the speed (or active force) for deforming material.When rotating
When measuring viscosity in rheometer, following shear thinning characteristic is observed: as shear rate increases and viscosity reduction.Hydrogel is aobvious
Plasticity is shown, it means that need certain shear stress (active force) before material starts to be easy flowing.The critical shear
Stress is frequently referred to as yield stress.Yield stress can be determined by the steady-flow curve of the rheometer measurement with Stress Control.
When the viscosity to be plotted as to the function of applied shear stress, it can be seen that sharply more than viscosity after critical shearing stress
Decline.Zero-shear viscosity and yield stress are to describe the most important rheological parameter of material suspending power.The two parameters can be non-
Different ranks is clearly distinguished, often so as to classify to rank.
The size of fibril or fibril beam depends on raw material and disintegrating method.Any suitable equipment can be used, as refiner,
Grinder, disperser, homogenizer, grater (colloider), friction glazed machine, sprayer of hammer crusher (pin mill), rotor-
Rotor dispergation machine, ultrasonic disruption device, Fluidizer (such as microfluidization device, big Fluidizer (macrofluidizer) or fluidisation type
Homogenizer) to carry out cellulosic material mechanical disintegration.Under conditions of there are enough water to prevent from forming key between fiber into
Row disintegration processing.
In an example, by using the disperser at least one rotor, blade or similar mechanically moving unit
It is disintegrated, the disperser is, for example, the rotor-rotor dispergation machine (rotor-rotor at least two rotors
dispergator).In disperser, when peripheral speed and rotation speed of the blade to be determined by radius (to the distance of shaft)
When rotating in opposite directions, the fibrous material in dispersion is hit repeatedly the other way around by the blade of rotor or arch rib.Due to
Fibrous material shifts outward radially, hits in the blade to be come the other way around with high peripheral speed one by one
On the wide surface of (i.e. arch rib);In other words, by the bump several times from opposite direction.Equally, in the width of blade
The edge (opposite edges of its edge and next rotor blade form paddle clearance) on surface (i.e. arch rib), is sheared
Power facilitates the disintegration of fiber and is detached from fibril.Collision frequency depends on the rotation speed of the rotor, quantity of rotor, each
The flow velocity that the quantity and dispersion of blade pass through device in rotor.
In rotor-rotor dispergation machine, fibrous material is introduced by the rotor reversely rotated, and in the following way
Be displaced outwardly along the radial direction relative to rotor shaft and take this and fibrillation occurs simultaneously: the material be repeatedly subjected to by
Shearing and impact force caused by different reverse rotation rotors.One example of rotor-rotor dispergation machine is Atrex device.
Another example for being adapted for the equipment of disintegration is sprayer of hammer crusher, such as multiple periphery sprayer of hammer crusher.This sets
A standby example is as described in US 6202946B1 comprising shell, and have in the shell and be equipped with impact surfaces
The first rotor;The second rotor that is concentric with the first rotor and being equipped with impact surfaces, second rotor are arranged to with first
The opposite direction of rotor rotates;Or the stator that is concentric and being equipped with impact surfaces with the first rotor.The equipment includes being located at shell
In feed opening and discharge hole on the central opening and shell wall of rotor or rotor and stator and to most external rotor or fixed
The peripheral openings of son.
In one embodiment, disintegration is carried out by using homogenizer.In homogenizer, work of the fibrous material in pressure
It homogenizes under.Fibrous material dispersion homogeneous chemical conversion nanometer fibril cellulose be by dispersion pressure it is through-flow caused by, this
So that material disintegration is fibril.Fibrous material dispersion passes through narrow through-flow gap at a given pressure, wherein dispersion is linear
The increase of speed makes dispersion by shearing force and impact force, causes to remove fibril from fibrous material.Fiber segment is in fibril
Changing disintegration in step is fibril.
Herein, term " fibrillation " refer generally to by particle work done (work) come mechanical disintegration fibrous material,
Middle cellulose fibril is detached from from fiber or fiber segment.The function can be based on various effects, such as grind, pulverize or shear or
Their combination, or can reduce other corresponding effects of particle size.Energy consumed by the function of purification is usually with energy
Amount/(material quantity of processing) indicates that unit is, for example, kilowatt hour/kilogram (kWh/kg), megawatt hour/ton, or with these at than
The unit of example.Statement " disintegration " or " disintegration processing " can be used interchangeably with " fibrillation ".
The fibrous material dispersion of experience fibrillation is the mixture of fibrous material and water, also referred herein as " slurry
Expect (pulp) ".Fibrous material dispersion may generally refer to entire fiber, therefrom separate part (segment), fibril beam or mixed with water
The fibril of conjunction, and generally, aqueous fiber material dispersion is the mixture of this dvielement, and wherein the ratio between component takes
Certainly in processing stage or processing stage, for example, same batch fibrous material number of run during processing or " passing through " it is secondary
Number.
A kind of mode of characterization nanometer fibril cellulose is using the viscous of the aqueous solution containing the nanometer fibril cellulose
Degree.Viscosity can be such as brookfield viscosity or zero-shear viscosity.As described herein, specific viscosity distinguish nanometer fibril cellulose with it is non-
Nanometer fibril cellulose.
In an example, a nanometer fibril fiber is measured with Brookfield viscometer (brookfield viscosity) or other corresponding equipment
The apparent viscosity of element.Suitably use paddle rotor (vane spindle) (No. 73).There are several commercially available Brookfield viscometers can
For measuring apparent viscosity, they are all based on identical principle.Suitably, RVDV spring (RVDV is used in a device
Spring) (Bu Shi RVDV-III).The sample of nanometer fibril cellulose is diluted to the concentration of 0.8 weight % with water, and is mixed
10 minutes.Diluted sample material is added in 250mL beaker, the temperature was then adjusted to 20 DEG C ± 1 DEG C, carries out if necessary
Heating, and mix.Use the slow-speed of revolution of 10rpm.
The viscosity that the nanometer fibril cellulose provided in the method as raw material can be provided in aqueous solution by it
To characterize.Viscosity describes the original fiber degree of such as nanometer fibril cellulose.In one embodiment, nanometer fibril fiber
Element provides at least 2000mPas measured under the consistency of 0.8% (w/w) and 10rpm when being dispersed in water, for example, at least
The brookfield viscosity of 3000mPas.In one embodiment, nanometer fibril cellulose is provided when being dispersed in water 0.8%
(w/w) at least brookfield viscosity of 10000mPas measured under consistency and 10rpm.In one embodiment, nanometer fibril
Cellulose provides at least cloth of 15000mPas measured under the consistency of 0.8% (w/w) and 10rpm when being dispersed in water
Family name's viscosity.The cloth that the nanometer fibril cellulose measures under the consistency of 0.8% (w/w) and 10rpm when being dispersed in water
The example of family name's range of viscosities include 2000-20000mPas, 3000-20000mPas, 10000-20000mPas,
15000–20000mPa·s、2000–25000mPa·s、3000–25000mPa·s、10000–25000mPa·s、15000–
25000mPas, 2000-30000mPas, 3000-30000mPas, 10000-30000mPas and 15000-
30000mPa·s。
In one embodiment, nanometer fibril cellulose includes unmodified nanometer fibril cellulose.Implement at one
In mode, nanometer fibril cellulose is unmodified nanometer fibril cellulose.It was found that the row of unmodified nanometer fibril cellulose
The obvious ratio of liquid such as anion rank is faster.Unmodified nanometer fibril cellulose usually have 0.8% (w/w) consistency and
The brookfield viscosity in 2000-10000mPas ranges measured under 10rpm.
The fibrous cellulose raw material of disintegration can be modified fibrous raw material.Modified fibrous raw material refers to fiber
It is subject to processing the raw material of influence, so that cellulose nanometer fibril is easier to be detached from from fiber.Usually suspended substance in liquid (is starched
Material) fibrous cellulose raw material existing for form is modified.
Chemically or physically property can be to the modification of fiber.In chemical modification, the chemistry knot of cellulosic molecule
Structure is changed by chemical reaction (" derivatization " of cellulose), preferably makes the length of cellulosic molecule unaffected but by functional group
It is added to the β-D- glucopyranose units of polymer.The chemical modification of cellulose occurs in a certain conversion degree, which takes
Certainly in the dosage of reactant and reaction condition, chemical modification is incomplete in principle, so that cellulose will be protected as fibril
It is not soluble in water to hold solid form.In physical modification, anionic, cationic or nonionisable substance or any combination thereof
Physical absorption is on cellulose surface.Modification is also possible to using enzyme.
Particularly, the cellulose after the modification in fiber can be ion live-wire, this is because the ion of cellulose
Charge reduces the interior keys of fiber, may consequently contribute to disintegration later to nanometer fibril cellulose.The chemistry of cellulose can be passed through
Modified or physical modification realizes ion live-wire.Compared with starting material, it is modified after fiber can anion with higher or
Cationic charge.It is that (wherein hydroxyl is oxidized for oxidation that is most generally used, which is used to prepare the chemical modification method of anionic charge,
For aldehyde and carboxyl), sulfonation and carboxy methylation.It in turn, can be by being connected to cation group (such as quaternary ammonium group)
Cellulose is cationized, to chemically generate cationic charge.
In one embodiment, nanometer fibril cellulose include chemical modification nanometer fibril cellulose, such as yin from
Son modified nanometer fibril cellulose or cation-modified nanometer fibril cellulose.In one embodiment, nanometer fibril
Cellulose is anion-modified nanometer fibril cellulose.In one embodiment, nanometer fibril cellulose is that cation changes
The nanometer fibril cellulose of property.In one embodiment, anion-modified nanometer fibril cellulose is that the nanometer of oxidation is former
Fine cellulose.In one embodiment, anion-modified nanometer fibril cellulose is the nanometer fibril cellulose of sulfonation.?
In one embodiment, anion-modified nanometer fibril cellulose is carboxymethylated nanometer fibril cellulose.Chemical modification
Nanometer fibril cellulose can be used for influencing the release profiles of certain activating agents.For example, anion rank can be used for discharging
Molecule with cationic charge is to obtain extended rate of release, and vice versa.
Cellulose can be oxidized.In the oxidation of cellulose, the primary hydroxyl of cellulose passes through heterocycle nitroxyl compound
(such as 2,2,6,6- tetramethyl piperidine -1- oxygroup free radicals, commonly referred to as " TEMPO ") carry out catalysis oxidation.Cellulose β-D-
The primary hydroxy group (C6- hydroxyl group) of glucopyranose units is selectively oxidized to carboxylic acid group.Also by primary hydroxyl shape
At some aldehyde radicals.About this discovery, i.e., suboxides degree can not achieve fibrillation effective enough and higher degree of oxidation
Cellulose degradation after causing mechanical damage to handle, cellulose can be oxidized to a level, in the fiber of oxidation under the level
It is starched in element by the carboxylic acid content that conductimetric titration measures for 0.6-1.4mmol COOH/g slurry or 0.8-1.2mmol COOH/g
Material, preferably 1.0-1.2mmol COOH/g slurry.When the fiber of the cellulose of thus obtained oxidation is disintegrated in water, it
The stable transparent dispersion of individual cellulose fibril is provided, the width of the individual cellulose fibril can be, for example, 3-
5nm.When the slurry of oxidation is as initial culture medium, the available brookfield viscosity measured under 0.8% (w/w) consistency is at least
Nanometer fibril cellulose for 10000mPas, for example in 10000-30000mPas ranges.
Catalyst " TEMPO " no matter when is referred in the present invention, it is evident that relates to the measurement and operation of " TEMPO "
All equally or be similarly applicable for TEMPO any derivative or arbitrarily being capable of C6 carbon in selective catalysis cellulose
The heterocycle nitroxyl free radical of the oxidation of hydroxyl group.
In one embodiment, the nanometer fibril cellulose of these chemical modifications is provided when being dispersed in water
At least brookfield viscosity of 10000mPas measured under the consistency and 10rpm of 0.8% (w/w).In one embodiment, this
The nanometer fibril celluloses of a little chemical modifications is provided when being dispersed in water to be measured under the consistency of 0.8% (w/w) and 10rpm
At least brookfield viscosity of 15000mPas.In one embodiment, the nanometer fibril cellulose of these chemical modifications is dispersing
At least brookfield viscosity of 18000mPas measured under the consistency of 0.8% (w/w) and 10rpm is provided when Yu Shuizhong.Used
The brookfield viscosity of the example of anion nanometer fibril cellulose is in 13000-15000mPas or 18000-20000mPas models
In enclosing, or even up to 25000mPas, this depends on the degree of fibrillation.
In one embodiment, nanometer fibril cellulose is the nanometer fibril cellulose of TEMPO oxidation.The material is low
High viscosity is provided under concentration, such as at least 20000mPas, even at least measured under 0.8% (w/w) consistency and 10rpm
The brookfield viscosity of 25000mPas.In an example, the nanometer fibril cellulose of TEMPO oxidation is in 0.8% (w/w) consistency
With the brookfield viscosity that is measured under 10rpm in the range of 20000-30000mPas, such as 25000-30000mPas.
In one embodiment, nanometer fibril cellulose includes the nanometer fibril cellulose of non-chemical modification.At one
In embodiment, the nanometer fibril cellulose of this non-chemical modification provides the consistency in 0.8% (w/w) when being dispersed in water
With at least 2000mPas measured under 10rpm, or the brookfield viscosity of at least 3000mPas.
Nanometer fibril cellulose can also come together to characterize by average diameter (or width) or average diameter with viscosity, institute
Stating viscosity is, for example, brookfield viscosity or zero-shear viscosity.In one embodiment, the fibril number of the nanometer fibril cellulose
Equal diameter range is 1-100nm.In one embodiment, the fibril number average diameter range of the nanometer fibril cellulose is 1-
50nm.In one embodiment, the fibril number average diameter range of the nanometer fibril cellulose is 2-15nm, such as TEMPO
The nanometer fibril cellulose of oxidation.
The diameter of fibril can be measured with multiple technologies (such as passing through microscope).It can be by aobvious to Field Emission Scanning Electron
Micro mirror (FE-SEM), transmission electron microscope (TEM) (such as low-temperature transmission electron microscope (cryo-TEM)) or atomic force are aobvious
The image that micro mirror (AFM) obtains carries out image analysis to measure the distribution of fibril thickness and width.In general, the most suitable tool of AFM and TEM
There is the nanometer fibril cellulose rank of narrow fibril diameter distribution.
In one example, at 22 DEG C, with the stress for being equipped with narrow gap blade geometry structure (diameter 28mm, length 42mm)
Controlled rotational rheometer (AR-G2, TA instrument company, Britain (TA Instruments, UK)), in the cylinder that diameter is 30mm
The rheology viscosity of nanometer fibril cellulose dispersion is measured in shape specimen cup.After sample is loaded into rheometer,
Make them static 5 minutes, starts to measure later.It is measured with the shear stress (it is proportional to the torque of application) gradually increased
Steady-state viscosity, and measure shear rate (it is proportional to angular speed).After reaching constant shear rate or at 2 minutes
After maximum time, the report viscosity (=shear stress/rate of shear) under a certain shear stress is recorded.When shear rate is more than
1000s-1When, stop measurement.This method can be used for measuring zero-shear viscosity.
In an example, nanometer fibril cellulose is provided when dispersed in water in 1000-100000Pas ranges
Zero-shear viscosities (" platform " of constant viscosity under small shear stress) interior, for example in 5000-50000Pas ranges, and
Yield stress (starting shear stress when shear thinning) in 1-50Pa range, for example in 3-15Pa ranges, these surveys
Amount is the result is that pass through what rotational rheometer measured in an aqueous medium under conditions of consistency is 0.5 weight % (w/w).
Turbidity be usually naked eyes fluid caused by sightless individual particles (all suspensions or dissolved solid)
It is muddy or fuzzy.Have it is several measurement turbidity practical ways, most directly be measure light pass through water sample capo when decaying (that is,
The reduction of intensity).The Jackson candle method (unit: jackson turbidity unit or JTU) alternatively used is substantially to survey in turn
It measures and completely obscured passes through water column length needed for candle flame seen in water column.
Turbidity can be quantitative determined using optical turbidity measuring instrument.There are some quantitative measurment turbidity of being commercially available for
Nephelometer.In the present invention, using the method based on turbidimetry.Turbidity unit from calibration nephometer is referred to as Nephelometric Turbidity
Unit (NTU).Measuring device (nephometer) is calibrated and controlled with standard calibration samples, later to diluted NFC sample
The turbidity of product measures.
In a kind of turbidimetry method, nanometer fibril cellulose sample is diluted in water lower than the nanometer fibril
The concentration of the gel point of cellulose measures the turbidity of dilute sample.Measure the described dense of nanometer turbidity of fibril cellulose sample
Degree is 0.1%.Using HACH P2100 nephelometer (Turbidometer) Lai Jinhang turbidimetry with 50mL measurement container.
0.5g sample (being calculated with dry matter) is loaded into measurement container, is used by the dry matter for measuring nanometer fibril cellulose sample
Tap water is filled to 500g, and is vigorously mixed about 30 seconds by oscillation.Aqueous mixture is divided into 5 measurement containers immediately,
It is inserted into nephelometer.3 measurements are carried out to each container.Average value and standard deviation are calculated from result obtained,
Final result unit is NTU unit.
A kind of mode for characterizing nanometer fibril cellulose is not only to have limited viscosity but also limited turbidity.Low turbidity indicates the small of fibril
Size, such as minor diameter, because small fibril is very poor to the scattering of light.In general, viscosity increases as original fiber degree increases
And at the same time haze reduction.However, this occurs before some point.When continuing fibrillation, fibril finally starts to rupture
And firm network cannot be re-formed.Therefore, after this point, turbidity and viscosity are all begun to decline.
In an example, the turbidity of anion nanometer fibril cellulose is lower than 90NTU, such as 3-90NTU, such as 5-
60NTU, such as 8-40NTU, these numerical value are measured in an aqueous medium under 0.1% (w/w) consistency by turbidimetry.?
In one example, the turbidity of natural nano fibril can even be higher than 200NTU, such as 10-220NTU, such as 20-200NTU,
Such as 50-200NTU, these numerical value are measured in an aqueous medium under 0.1% (w/w) consistency by turbidimetry.In order to characterize
Nanometer fibril cellulose, can combine these ranges with the range of viscosities of nanometer fibril cellulose, such as nanometer fibril fiber
Element provides at least 2000mPas measured under the consistency of 0.8% (w/w) and 10rpm when being dispersed in water, at least
3000mPas, at least 5000mPas, for example, at least 10000mPas, for example, at least brookfield viscosity of 15000mPas.
The raw material for being used to prepare method is usually the nanometer fibril fibre directly obtained by the disintegration of above-mentioned some fibre raw material
Dimension element, they are evenly distributed in water due to disintegration condition with low concentration.Raw material can be the water that concentration is 0.2-10%
Property gel.
In one embodiment, before freeze-drying, the concentration range of the nanometer fibril cellulose in hydrogel is 0.5-
10%, 1-10%, such as 2-8% or 1-7%.Preferred scope for major applications is 3-7%, 4-7% or 4-8%.?
In test, the concentration of 3% and 6.5% these close range endpoints of concentration representative is selected.It can be by the gel that is freeze-dried
The hydrogel of same concentrations is rebuild after freeze-drying.More particularly, the redispersible Yu Shuizhong of dry gel, and work as redisperse
The dispersion concentration provided when in water be such as 0.1-10% (w/w), such as 0.5-2.0% (w/w) or 2-8% (w/w) or
3-7% (w/w), viscograph are equal or substantially equal to its initial viscosity curve having under identical dispersion concentration.
Polyethylene glycol
Polyethylene glycol (PEG) is polyether compound, depends on its molecular weight, also referred to as polyethylene oxide (PEO) or polyoxy
Ethylene (POE).The structure of PEG is typically expressed as H- (O-CH2-CH2)n-OH.In general, the polymerization that polyethylene glycol passes through ethylene oxide
It prepares, and the commercially available polyethylene glycol for buying 300g/mol to 10000000g/mol wide range of molecular weights.Polyethylene glycol is
It is water-soluble, and it is with hypotoxicity.
In one embodiment, the molecular weight ranges of polyethylene glycol are 100-10000kDa, such as 1000-
10000kDa.In one embodiment, the molecular weight ranges of polyethylene glycol are 3000-8000kDa, such as 5000-
7000kDa, such as from about 6000kDa." molecular weight " used in the disclosure can be number-average molecular weight.In general, the number of polymer is equal
Molecular weight can measure by the following method: such as gel permeation chromatography, by [mark-person of outstanding talent's Brunswick (Mark-Houwink) side
Journey] viscosimetry, colligative property method, such as vapour pressure osmometry, end group measurement or proton NMR.
Trehalose
Trehalose (also referred to as a, a-trehalose;α-D- glucopyranosyl-(1 → 1)-α-D-g glucopyranoside,
Mycose or tremalose) it is by the α between two phlorose units, α -1,1- glucoside bond is formed by naturally
α-connection disaccharides.Trehalose is nutritionally suitable with glucose, because it resolves into rapidly glucose by trehalase.Sea
Algae sugar can exist in the form of anhydrous or dihydrate.In one embodiment, trehalose is D (+)-trehalose dehydrate
(trehalose dehydrate), it is compatible with nanometer fibril cellulose.In one example, trehalose is D- (+)-dehydration sea
Algae sugar.It can be provided or be dissolved in solid form in aqueous medium (such as water).
Prepare lyophilisation product
The described method includes: providing ingredient nanometer fibril cellulose, acellular tissue extract, polyethylene glycol and seaweed
Sugar, the nanometer fibril cellulose are usually aqueous suspension or hydrogel.In one embodiment, nanometer fibril cellulose
It is unique cellulosic material in aqueous suspension or hydrogel.In one embodiment, nanometer fibril cellulose be
Sole polymer gel-forming material in aqueous suspension or hydrogel.In one example, aqueous suspension or hydrogel packet
Containing a certain amount of other fibrous materials (for example, non-nano fibril cellulose), such as the amount is fibrous material dry weight
0.1-2% (w/w).
The described method includes: providing the hydrogel comprising nanometer fibril cellulose.Nanometer fibril cellulose in hydrogel
Concentration range can be 0.1-10% (w/w), 0.5-10% (w/w) or 1-10% (w/w), such as 2-8% (w/w).For big
The preferred scope of certain applications is 3-6.5% (w/w)), 2.5-7% (w/w), 3-7% (w/w), 4-7% (w/w) or 4-8%
(w/w)。
The described method includes: providing the acellular tissue extract comprising bioactive substance mixture, acellular tissue
The concentration of extract can be defined as in hydrogel or mixture cell-free group in the wet substance of extract, hydrogel or mixture
Dried protein content in the dry content or hydrogel or mixture of extract is knitted, above-mentioned hydrogel or mixture are preferably most
Whole hydrogel or the mixture containing all the components.The dry content model of acellular tissue extract in hydrogel or mixture
It encloses and can be 0.01-20% (w/w).By the dry content for the acellular tissue extract that the gross mass of hydrogel or mixture calculates
Range can be 0.01-10% (w/w), for example, 0.05-10% (w/w).In one embodiment, by hydrogel or mixing
The dry content range of acellular tissue extract can be 0.1-5% (w/ in the hydrogel or mixture that the gross mass of object calculates
W), for example, 0.1-3% (w/w), 0.5-3.5% (w/w) or 0.5-5% (w/w).In one embodiment, acellular tissue
The dry content of extract refers to total dried protein content of acellular tissue extract.
The method also includes: mixing hydrogel, acellular tissue extract, polyethylene glycol and trehalose are to be mixed
Object.It includes nanometer fibril cellulose, acellular tissue extract, poly- second two that the ingredient, which can be mixed with random order to obtain,
The aqueous mixture of pure and mild trehalose.In one embodiment, it is calculated by the gross mass of mixture, mixture includes 0.1-
The polyethylene glycol of 2% (w/w) and/or the trehalose of 0.05-1.0 (w/w).In one embodiment, by total matter of mixture
Amount calculates, and mixture includes the polyethylene glycol of 0.1-2% (w/w) and/or the trehalose of 0.1-0.5 (w/w).In an embodiment party
It in formula, is calculated by the gross mass of mixture, mixture includes the polyethylene glycol and/or 0.1-0.5 (w/w) of 0.5-1.5% (w/w)
Trehalose.In one embodiment, it is calculated by the gross mass of mixture, mixture includes the poly- second of 0.5-1.5% (w/w)
The trehalose of glycol and/or 0.3-0.4 (w/w).The mixture is the form of hydrogel, and it is referred to as hydrogel,
The more particularly hydrogel comprising nanometer fibril cellulose and preferred other ingredients, other ingredients be such as polyethylene glycol,
Trehalose and/or other ingredients (such as acellular tissue extract and other possible activating agents as described herein).One
In a embodiment, the amount of trehalose is 5-100mmol, such as 10-50mmol in mixture.Mixing can be used suitable
Mixing machine or homogenizer carry out, or can as done in the experiment that laboratory scale carries out, pass through connect two
A syringe containing mixture and duplicate injection mixture carrys out blending constituent between syringe, to realize mixing and/or
Matter.
The ratio of dry nanometer fibril cellulose and cryoprotector (NFC:PEG: trehalose by weight) in gel
It can be for example, about 9.5:3:1 to 20:3:1, the range is for testing.In some instances, nanometer fibril fiber is done in gel
Element is 5-40:2-6:1,9-22:2-5:1 or 9.5-20 with the ratio of cryoprotector (NFC:PEG: trehalose) by weight:
2-5:1 or 9-22:2-4:1 or 9.5-20:2-4:1, for example, about 10:5:1, about 15:5:1, about 10:3:1, about 15:3:1 or
About 20:3:1.
Gained mixture can be freeze-dried, that is, freezing dry process is physical to dry nanometer fibril gel
Matter has no significant effect.Mixture can also become the hydrogel that can be freeze-dried.One example of the physical property is by water
Gel discharges the curve of reagent, the reagent such as small molecule or macromolecular, such as the substance in acellular tissue extract, or
Other therapeutic agents or enamel.The different molecular of different molecular weight is found to have (including relatively small organic molecule and larger
Protein) can similar release profiles from hydrogel controlled release.Available molecular weight ranges are very wide, such as in testing, can
With molecule of the controlled release molecular weight in about 170-70000g/mol (dalton) range.However, the molecular proportion with high molecular weight
Molecule with lower molecular weight discharges slowly.
In one embodiment, the method also includes: one or more therapeutic agents are provided, and mixing treatment agent with
Hydrogel, acellular tissue extract, polyethylene glycol and trehalose, that is, therapeutic agent is added to mixture.It can be in addition nothing
One or more therapeutic agents are added while cell tissue extract, polyethylene glycol and/or trehalose, or can be before this
Or elements addition agent later.
In one embodiment, the method also includes: one or more enamels are provided, and mix enamel with
Hydrogel, acellular tissue extract, polyethylene glycol and trehalose, that is, enamel is added to mixture.It can be poly- in addition
One or more enamels are added while ethylene glycol and/or trehalose, or can add enamel before this or later.
The combination of therapeutic agent and enamel can also be used.
It is freeze-dried after obtaining the mixture to obtain the dry hydrogel containing nanometer fibril cellulose.It can
To use any appropriate freeze-drying method.Freeze-drying (alternatively referred to as be lyophilized) be it is a kind of using rapid cooling in system
Interior generation thermodynamic phase simultaneously leads to the method mutually separated.Then solvent is removed by distilling under vacuum, in its elder generation
Before leave a void in the region that occupies.Distillation refer to substance directly from solid be changed into gas phase and without intermediate fluid phase.Distillation
It is in its phasor lower than the heat absorption phase transformation occurred under the temperature and pressure of substance three phase point.
In one embodiment, freeze-drying includes that the temperature of mixture is down at least -30 DEG C first, such as extremely
It is-40 DEG C few, such as-30-- 100 DEG C, or-40-- 100 DEG C are reduced to, or be even reduced to-200 DEG C or lower, for example, working as
When using liquid nitrogen, apply the pressure of reduction then with removing water from the mixture.In general, mixture should apply reduced pressure
It is freezed when power.In one embodiment, during applying reduced pressure and after applying minimum pressure, temperature liter
Height, such as temperature are increased to about -20 DEG C or even rise to about 10 DEG C.Temperature can be increased before applying reduced pressure, or
Person can increase temperature during applying reduced pressure.
In one example, freeze-drying is implemented by being freezed with liquid nitrogen to mixture.For example, mixture will be contained
Bottle immerse liquid nitrogen in until mixture freeze.Hereafter, apply reduced pressure to mixture to go to remove water from mixture.Drop
Vacuum needed for low pressure can refer to acquisition water sublimate.Since the required vacuum pressure under three phase point occurs for the distillation of water
Depending on temperature used.
As used herein, " drying " typically refers to be dehydrated, these terms are used interchangeably, wherein are removed from hydrogel
Hydrogel of the water to be dried or be dehydrated.In one embodiment, continue freeze-drying until hydrogel is with required
Water content or freeze-drying continue to minimum moisture content, and the minimum moisture content is preferably shorter than 20%, or more preferably less than 10%,
Or even lower than 5%, for example, water content is 1-20%, 2-20% or 2-10% (w/w).In one embodiment, continue cold
Be lyophilized it is dry, until hydrogel water content ranges be 2-8%, 2-6%, 2-5% or 1-5% (w/w).It is lower than 2% in general, obtaining
Water content may be challenging.It, can be in vacuum or protective gas by dry product after obtaining low water content
It is packaged.This will prevent dry absorbed environment aqueous vapor, and absorbing environment aqueous vapor may make water content ranges be increased to
Such as 4-8% or 5-7% (w/w).The hydrogel of drying obtained can be by adding waterborne liquid (such as water) and making
Dry product suspends and gelation again.Gelation or the hydrogel to suspend again again are obtained, can be had identical as before drying
Concentration and water content.The hydrogel provides the characteristic essentially identical with the initial hydrogel before drying.
The drying comprising nanometer fibril cellulose is obtained using the freeze-drying method of embodiments disclosed herein
Final hydrogel, the hydrogel being more particularly freeze-dried, the nanometer fibril cellulose include acellular tissue extract.
It includes nanometer fibril cellulose, acellular tissue extract, polyethylene glycol and trehalose that one embodiment, which provides,
Drying hydrogel, the acellular tissue extract include bioactive substance mixture, wherein dry hydrogel
Water content be 10% (w/w) or lower, or be lower than 10% (w/w), such as 1-20% (w/w) or 2-10% (w/w), as before
Described in text.
The hydrogel of freeze-drying is also referred to as aeroge, the aeroge being especially freeze-dried.It is defined according to one, airsetting
Glue is derived from the porous super light material of gel, wherein the liquid component of gel is by gas instead.Although entitled aeroge, airsetting
Glue is firm, rigid and dry material, and physical property is unlike gel: the name is made of gel from them.
In one embodiment, the dry content range of acellular tissue extract is 0.1-65% in dry hydrogel
(w/w) or 0.1-50% (w/w), such as 1-25% (w/w) or 1-20% (w/w), 1-10% (w/w), 1-5% (w/w),
Or 20-65% (w/w), 10-65% (w/w), 5-65% (w/w), 10-50% (w/w), 5-50% (w/w), 5-25% (w/w),
5-20% (w/w) or 5-15% (w/w).These ranges also include any possible therapeutic agent.
In one embodiment, in dry hydrogel, polyethyleneglycol content range is 1-20% (w/w), and/
Or the content range of trehalose is 0.5-10% (w/w).In one embodiment, in dry hydrogel, poly- second two
Alcohol content range is 5-15% (w/w) and/or the content range of trehalose is 3-4% (w/w).
Dry hydrogel can by be generally suitable for required goals of medicine sheet material, block or other shapes or in the form of mention
For that then can rewet using preceding to obtain the medical gel for being suitable for target (such as wound).Dry hydrogel can also
It is provided in the form of powder or other crushing.In this case, the method for preparing product may include example the step of forming powder
Such as by the way that the product of freeze-drying is ground or crushed.
Hydrogel obtained can be used for various applications, such as those described herein before the drying or later, such as
For the method to Object delivery substance.Hydrogel can also be provided as medical product.
Medical product
Medical product in hydrogel containing tissue extract can be used for a variety of applications.One specific field is that medicine is answered
With wherein material is applied in living tissue, such as is administered on skin.These materials can be used for medical product, such as patch, apply
Material, bandage and filter etc..Medical product is also possible to treatment product, such as treatment patch or gel containing medicament.In general,
The surface of product comprising nanometer fibril cellulose will during use with skin contact.When nanometer fibril cellulose surface and skin
When skin directly contacts, it can provide advantageous effect, such as it can promote the healing of other damages on wound or skin, or
Person it substance can be promoted to be delivered to skin from medical product.
As used herein, term " wound " refer on tissue (such as skin, mucous membrane or subcutaneous tissue) it is any damage, by
Wound, disease, illness etc., including open or closed wound, wherein the healing of wound is desired and can use institute herein
The product stated promotes.Wound can be clean, pollution, infection or field planting, wherein especially in rear some cases
In, therapeutic agent, such as antibiotic can be given.The example of open wound includes scratch, avulsion, notch, lacerated wound, punctures wound
And perforating wound.The example of closure wound includes hemotoncus, crush injury, sew up a wound, graft and any skin, skin disease or
Skin disorder.The example of skin disorder, skin disease or skin disease includes acne, infection, vesica disease, herpes labialis, skin beads
Bacterium disease, cellulitis, dermatitis and eczema, bleb, nettle rash, lupus, the papule scales of skin that peel off, rubeola and erythema, psoriasis, erythema Cuo
Sore, radiation associated disease, pigmentation, mucoprotein keratosis, ulcer, atrophy and necrosis progrediens, vasculitis, leucoderma,
Wart, neutrophil cell and eosinophil disease, congenital disorders, tumour and cancer, such as melanoma and epidermis or corium
The Other diseases or illness of tumour or epidermis and corium.
The medical product for further including therapeutic agent can be provided, wherein contain in nanometer fibril cellulose and mention in a organized way
The hydrogel for taking object also includes one or more therapeutic agents, for example, bioactivator, activating agent, medicament or drug.Term medicament
It can also be used interchangeably with term therapeutic agent.These reagents are activity or effective reagent, are usually existed with effective quantity.Treatment
Agent can be provided with salt, ester, amide, prodrug, conjugate, active metabolite, isomers, the forms such as segment, analog.The reagent can
Whole body or local action are generated in object.Such reagent can be provided with predetermined amount, for example, the amount is configured in a timing
Between the reagent of desired amount is provided during section, and/or be configured to provide desired effect to target (such as skin or other tissues)
Fruit.The content range of therapeutic agent in the product can be, for example, 0.01-20% (w/w), for example, 0.05-10% (w/w).One
In a embodiment, the content range of therapeutic agent in the product is 0.1-5% (w/w), for example, 0.1-3% (w/w), 0.5-
3.5% (w/w) or 0.5-5% (w/w).Especially if can then provide the controlled release of reagent comprising therapeutic agent, persistently release
It puts or extended release.In this case, nanometer fibril cellulose can contain portion of water, so that reagent can permeate.
Therapeutic agent can be with water-soluble form, and fat-soluble form or emulsion form exist, or by it is other it is suitable in the form of exist.
Being further included in the example of therapeutic agent or bioactivator in medical product described herein includes: protein, peptide,
Carbohydrate, lipid, nucleic acid or its segment, preferable separate;Antibiotic, anodyne, such as lidocaine;Opiates medicine
Object, such as fentanyl or buprenorphine;Nicotine;Hormone, such as estrogen, contraceptive or androgen, such as testosterone;Nitroglycerin;East
Hyoscyamine;Clonidine;Antidepressants, such as selegiline;ADHD drug, such as methylphenidate;Vitamin, such as B12 or the dimension life of cyanogen cobalt
Element;5-hydroxyryptophan;Alzheimer's disease drug, such as rivastigmine;Acne drug;Antipsoriatic, glucocorticoid
Such as hydrocortisone;Antiandrogen, such as double fluorine draw Lip river (bifluranol), Cyoctol (cyoctol), cyproterone, ground horse
Progesterone acetate, Flutamide (flutimide), Nilutamide and oxendolone (oxendolone);Antiestrogenic, such as horse are pregnant
Ketone acetate, ethamoxytriphetol, tamoxifen and Toremifene;Antimicrobial;Anesthetic;Antalgesic;Anti-inflammatory compound
Or reagent;Antihistamine;Beta blocker;Growth factor;Immunomodulator or medicament for treating skin disease or illness.Tissue
Extract can be contained in individually or together with one or more therapeutic agents and for example use on healthy skin or damaged skin
Medical paster, to provide therapeutic agent from the extended release of patch, sustained release or sustained release, such as within the time of a few hours, institute
A few hours are stated up to 6,12,24 or even 48 hours.
" extended release ", also referred to as time controlled released, sustained release or sustained release refer to drug or the load with medicine dipping
Body, designed for delivering the drug of doses within extended period.Purpose is that drug concentration is maintained to treatment window
Interior longest or desired time.The term is commonly used in the context of peroral dosage form.In addition to pill, capsule and injectable drug
Except carrier (usually have additional release function), the form of controlled release drug includes gel, implantation material and device and transdermal
Patch.In European Pharmacopoeia is defined as: " extended release dosage form formula is a kind of release dosage form of improvement, shows active material
Conventional release dosage form of the release than being given by identical approach release it is slower.Pass through special formulation design and/or manufacturer
Method realizes extended release.Equivalent terms: sustained-release dosage type."
One embodiment provides the medical product for further including antibiotic agent.This product is especially suitable for treatment
Wound, wherein Wound healing and bone regeneration characteristic is the same as preventing the antibiotic characteristic infected caused by harmful microorganism in wound from combining.Properly
Antibiotic example particularly including topical antibiotics, such as bacitracin, erythromycin, clindamycin, gentamicin, neomycin,
Polymyxins, mupirocin, tetracycline, first duomycin, (sodium) sulfacetamide, benzoyl peroxide and azelaic acid and it
Combination.Other types of antibiotic, such as systemic antibiotics, such as penicillins can also be provided, such as phenoxy group first
Base penicillin, flucloxacillin and Amoxicillin;Cephalosporins, such as Cefaclor and cefadroxil;Tetracyclines, such as Fourth Ring
Element, fortimicin and lymecycline;Aminoglycoside, such as gentamicin and tobramycin;Macrolides, such as erythromycin,
Azithromycin and clarithromycin;Clindamycin;Sulfamido and trimethoprim;Metronidazole and Tinidazole;Quinolones, such as cyclopropyl sand
Star, lavo-ofloxacin and Norfloxacin.
The example of androgen includes boldenone, Fluoxymesterone, mestanolone, mesterolone, methandrostenolone, 17- methyl
Testosterone, 17- Alpha-Methyl testosterone 3- cyclopentyl enol ether, Norethandrolone, Methylestrenolone*, oxandrolone, methylol testosterone, Oxymetholone
(oxymetholone), Prasterone (Prasterone), Si Tanlong ketone (Stanlolone), Stanozolol, testosterone, testosterone
17- trichloroacetaldehyde hemiacetal (chloral hemiacetal), testosterone 17- β-cipionate, testosterone enanthatas, testosterone nicotinate,
Testosterone Phenylacetate (testosterone pheynylacetate), testosterone propionate and thioetroxyl ketone.
The example that may include the antibiotic in hydrogel includes: aminoglycoside (for example, tobramycin, A meter Ka
Star, gentamicin, kanamycins, Netilmicin, tobramycin, streptomysin, azithromycin, clarithromycin, erythromycin are new mould
Element, erythromycin ester/ethylsuccinate/ester, gluceptate/Lactobionate/stearate/ester (stea rate)), β-is interior
Amides such as penicillin (such as benzyl penicillin, ospen, methicillin, naphthlazole, oxacillin, Cloxacillin, double chlorine moulds
Element, ampicillin, Amoxicillin, Ticarcillin, carbenicillin, mezlocillin, azlocillin and Piperacillin), cephalo
Rhzomorph (such as cefoxitin, cephazoline, Cefaclor, Cefamandole, Cefoxitin, cefuroxime, cefonicid, cephalo beauty
Azoles, cefotetan, Cefprozil, Loracarbef, cefetamet, cefoperazone, cefotaxime, Ceftizoxime, ceftriaxone, head
His pyridine of spore, Cefepime, Cefixime, Cefpodoxime and Cefsulodin), fluoroquinolones (such as Ciprofloxacin), carbon is green
Mould alkenes (such as Imipenem), Tetracyclines (such as Doxycycline, minocycline, tetracycline), macrolides (such as erythromycin and
Clarithromycin), monobactam (for example, aztreonam), quinolones is (for example, fleraxacin, acidum nalidixicum, Norfloxacin, cyclopropyl are husky
Star, Ofloxacin, Enoxacin, Lomefloxacin and cinoxacin), glycopeptide class (for example, vancomycin, teicoplanin), chlorine is mould
Element, clindamycin, trimethoprim, sulfamethoxazole, furantoin, rifampin and mupirocin and polymyxins such as PMB,
Oxazolidone, imidazoles (such as Miconazole, ketoconazole, clotrimazole, econazole, according to health azoles, bifonazole, butoconazole, benzene thiazole,
Isoconazole, Oxiconazole, Sertaconazole (sertaconazole), sulconazole and tioconazole), triazole type (such as Fluconazole, she
Triaconazole, end Saperconazole, ravuconazole, posaconazole, voriconazole, terconazole and albaconazole), thiazoles is (for example, Ah bar
Fragrant net (abagungin)) and propylamine (such as Terbinafine, Naftifine and Butenafine), echinocandin class (for example, Ah
Nifungin (anidulafungin), Caspofungin (caspofungin) and mikafen (micafungin)).Other antibiotic
May include polygodial, benzoic acid, Ciclopirox, Tolnaftate, undecenoic acid, Flucytosine or 5-flurocytosine, griseofulvin and
Haloprogin.
Also antibiotic treatment acne, such as clindamycin, erythromycin, Doxycycline, tetracycline etc. can be used.It can be with
Use other reagents, such as benzoyl peroxide, salicylic acid, topical retinoid A drug, such as vitamin A acid, Adapalene
Or tazarotene, azelaic acid or endocrine therapy agent such as spirolactone.For example, can with steroids corticosteroid, moisturizer,
Calcipotriene, coal tar, vitamin D, biostearin, tazarotene, anthraline, salicylic acid, methotrexate (MTX) or cyclosporin therapy
Psoriasis.Hydrocortisone, fat of Oromaius norvaehollandeae, apricot kernel oil, ammonia, bisabolol, papain, diphenyl hydrogenated amines, gold can be used
The reagent processing insect bites of honeysuckle flower extract or calamine etc or toxicodendron exposure (poison ivy exposure).These
Or some in other inorganic agents can also be classified as enamel.
The example that may include the antimicrobial in hydrogel includes Argent grain, especially silver nano-grain, release silver
The reagent or compound of ion, chlorhexidine gluconate and poly hexamethylene biguanide.
It may include that the example of the anesthetic in hydrogel includes procaine, benzocainum, chloroprocanine, can block
Cause, cyclohexyl methyl cacaine, dimethocaine, pyrocain (piperocaine), propoxycaine, procaine, procaine hydrochloride, third
U.S. cacaine, totokaine, lidocaine, Articaine, Bupivacaine, cincaine (cinchocaine), Etidocaine, Zuo Bu
Than cacaine, mepivacaine, prilocaine, Ropivacaine and Sibutramine Hydrochloride cacaine.In some embodiments, anesthetic is lidocaine
With the combination of prilocaine.
The example that may include the antalgesic in hydrogel includes opioid drug and the like.Illustrative opiates
Drug includes morphine, codeine, Oxycodone, hydrocodone, paramorphane, pethidine, buprenorphine, C16H25NO2, fentanyl and text
Daraf(reciprocal of farad) is pungent.
The example that may include the anti-inflammatory compound in hydrogel includes hydrocortisone, cortisone, dexamethasone, fluorine
Easily, Triamcinolone acetonide, Medroxyprogesterone, prednisolone, fludroxycortide (flurandrenolide), prednisone, halcinonidedcorten
(halcinonide), methylprednisolone, prednisone, Halcinonide (halcinonide), fludrocortison, cortisone, right
Flumethasone (paramethasone), betamethasone, brufen (ibuprophen), naproxen, fenoprofen, fenbufen, fluorine ratio
Ibuprofen, indoprofen, Ketoprofen, suprofen, Indomethacin, piroxicam, acetylsalicylic acid, salicylic acid, Diflunisal, bigcatkin willow
Sour methyl esters, phenylbutazone, sulindac, mefenamic acid, meclofenamate sodium and MCN 2559.
The example that may include the antihistamine in hydrogel includes diphenhydramine, dramamine, perphenazine, Qu Puli
Pyridine, pyrilamine, chloreyclizine, fenazil, carbinoxamine (carbinoxamine), Tripelennamine (tripelennamine), bromobenzene
That quick, hydroxyzine, marezine (cyclizine), meclizine (meclizine), Clorprenaline, RMI 9918 and chlorphenamine.
The example that may include the growth factor in hydrogel includes vascular endothelial growth factor (" VEGF "), nerve growth
The factor, such as NGF- β, platelet derived growth factor (PDGF), fibroblast growth factor, including for example, aFGF and
BFGF, epidermal growth factor (EGF), keratinocyte growth factor, tumor necrosis factor, transforming growth factor (TGF), including but
It is not limited to TGF- α and TGF-β, including TGF-β 1, TGF-β 2, TGF-β 3, TGF-β 4 or TGF-β 5, insulin like growth factor-1
With-II (IGF-I and IGF-II), des (- 1-3)-IGF-I (brain IGF-1), neurenergen 3 (NT-3) and brain source nerve
Trophic factors (BDNF).
The example that may include the immunomodulator in hydrogel includes cyclosporin A, amidine hydrazone, imuran, first ammonia butterfly
Purine, cyclophosphamide and tacrolimus.
One embodiment provides the medical product comprising hydrogel described in the text, such as dressing, patch or filtrate.
The hydrogel of freeze-drying as described herein can be used as implantation material offer, or as any other suitable medical treatment
Device provides, such as delivery apparatus, is configured to be introduced into or be implanted into the body of object, such as patient or has any of this needs
Other objects.The implantation material of medical aquogel comprising freeze-drying can be introduced into tissue, body cavity or other positions so that
Hydrogel is exposed to body fluid or other aqueous environments.The surface area of implantation material is 10-1000mm2, such as 300-600mm2。
Implantation material can have right dimensions and shapes, for example, cylindrical.In an example, the length of cylindrical implantation material
Degree range is 5-60mm, and diameter range is 1.5-5mm.Implantation material can carry out rehydration or wetting before implantation, or
Aquation in vivo can be set into after the implantation in it.
One embodiment provides the hydrogel for treating and/or covering skin wound or other damages, contains
Acellular tissue extract, particularly adipose tissue extract.One embodiment provides such hydrogel, is used as and applies
Material or patch, or be used in dressing or patch, for treating and/or covering skin wound or other damages.
One embodiment is provided for treating and/or covering sub-dermal soft tissue damage (for example, by wound, other damages
Wound or perform the operation caused by sub-dermal soft tissue damage) hydrogel, mentioned containing acellular tissue extract, particularly adipose tissue
Take object.
One embodiment is provided for treating and/or covering the skin for being transplanted object (such as skin graft) and covering
The hydrogel of wound, the hydrogel contain acellular tissue extract, particularly adipose tissue extract.One embodiment
Hydrogel is provided, is used as dressing or patch, or for being transplanted object (example for treating and/or covering in dressing or patch
Such as skin graft) skin wound of covering, the hydrogel contains acellular tissue extract, particularly adipose tissue and extracts
Object.
One embodiment provides hydrogel, for giving other therapeutic agent, more specifically one or more controlling
The purposes of agent is treated, the hydrogel contains acellular tissue extract, particularly adipose tissue extract.In an example,
Hydrogel can provide as former state, such as be provided in the form of patch.In an example, hydrogel can be with injectable
Form provides.One or more therapeutic agents can by comprising (such as dipping) in hydrogel as described herein, and to patient
Give can be it is percutaneous, transdermal or subcutaneous.
One embodiment provides the beauty product comprising the hydrogel, such as dressing, facial mask or patch, the water-setting
Glue contains acellular tissue extract, particularly adipose tissue extract.This product is referred to as beauty product.Product can
To provide with various shape, such as facial mask can be designed to be suitble to face, such as eyes lower section or chin, nose or forehead
On.One embodiment provides the purposes that hydrogel is used as beauty product.The product can be used for one or more enamels
It is released to user, such as is released to the skin of user.This beauty product may include one or more enamels.Beauty
Agent may include (such as dipping) in the product, and enamel will be released or deliver from the product.Enamel containing in the product
Amount can be for example in the range of 0.01-20% (w/w), such as 0.05-10% (w/w).In one embodiment, enamel
Content in the product is in the range of 0.1-5% (w/w), such as 0.1-3% (w/w) or 0.5-5% (w/w).Enamel can
With with similarly exist or provide in the product described in therapeutic agent above, vice versa.Beautifying use can be similar to herein
The medical application, especially gives therapeutic agent.Enamel can also be used for beauty therapeutic skin disease or illness, such as herein
Those of refer to.Such beauty product can be used for for example treating papule, acne skin, foxiness, wrinkle, Oily, stemness
Skin, aging skin, arachnoid blood vessel, erythema after solarization, black eye etc..The example of Beauty sticking piece includes skin cleaner, such as
Pore detergent, blackhead-removing agent, tension bar paste sheet-type packs, short patch and treatment patch overnight in short term.
The example of enamel includes the form of vitamin and its precursor, such as vitamin A;Such as biostearin, such as retinene
(retina), retinoic acid, retinyl palmitate and retinoic acid retinyl ester, ascorbic acid, 'alpha '-hydroxy acids such as glycolic and lactic acid;
Ethylene glycol;Biological technology products;Keratolytic;Amino acid;Antibacterial agent;Moisturizer;Pigment;Antioxidant;Plant extract
Object;Detergent or makeup removing agent;Anti-cellulite rouge agent, such as caffeine, carnitine, ginkgo and horse chestnut;Conditioner;Aromatic such as fragrance fumette
And perfume;Wetting agent such as urea, hyaluronic acid, lactic acid and glycerol;Emollient such as lanolin, triglycerides and aliphatic ester;FR
Scavenger, single line oxygen scavenger, superoxides scavenger or hydrogen peroxide scavenger, such as ascorbic acid (vitamin C), paddy Guang
Sweet peptide, tocopherol (vitamin E), carotenoid, Co-Q10, bilirubin, lipoic acid, uric acid, enzyme simulation agent, Idebenone,
Polyphenol, selenium, spin traps such as phenyl butyl nitrone (PBN), protein methionine group, superoxide dismutase, peroxide
Change hydrogen enzyme, selenium peroxidase, Heme oxygenase etc. or their combination.Enamel can be fat-soluble with water-soluble form
Form or emulsion form exist, or exist in the form of other are suitable.
Medical or beauty hydrogel as described herein can be mixed or is packaged in application device, and the application device is
Such as syringe, medicator, pump or pipe, containing the desired amount of hydrogel, such as having a size of 0.5ml to 200ml or even more
Big syringe.The device may include mouthpiece (mouthpiece) or nozzle, for providing required thickness and width and geometry
The constant water stream of gel of shape.In an example, hydrogel is to make it possible to for example pass through needle with a certain concentration and viscosity
Or the injectable forms injected by syringe interface part or nozzle.The hydrogel of freeze-drying can provide be packaged in it is close
Form in package dress provides, for example, being packaged in vacuum packaging or the packaging containing protective gas.Hydrogel, especially
The hydrogel of freeze-dried can be implantation material form, can be such as medical capsule.Hydrogel can be
Wound or the sheet material of other targets etc. can be applied to after wetting.These " instant " devices can be packed, and sterilize and store, and
It is used when needing.These application devices may be embodied in instant kit.The hydrogel of freeze-drying or production containing it
Water content ranges in product (such as containing the product of therapeutic agent) are 2-10% (w/w), such as 2-8% (w/w), 1-5% (w/w),
2-5% (w/w) or 5-7% (w/w).In an example, for example, being provided with the independent appearance of the liquid comprising predetermined amount in packaging
Device, the liquid are that for example water, saline solution, buffer solution or similar waterborne liquid, the predetermined amount are arranged to make gel again
Aquation is at required water content, as described herein.Liquid, or packet can be for example provided in syringe or similar applicator
Dress may include the independent compartment for liquid, may be coupled to another compartment comprising dried hydrogel, such as by pressing
Briquetting fills and destroys sealing or similarly liquid made to contact with each other with desiccant gel.
One embodiment provides the method for cosmetic treatments skin, and the method includes by medical treatment as described herein
Product or beauty product are administered on skin.
One embodiment provides the medical product or beauty product as described herein being packaged in independent packaging.Individually
Packaging can be used as a series of packagings and provide.Usually such packaging product is provided with sterilized form.
One embodiment provides the examination comprising medical product as described herein or beauty product (such as packaging product)
Agent box, wherein kit may include one or more packaging products.Kit can also include other materials or equipment, example
Such as, for carrying out pretreated container to product using preceding, the container contains water or other waterborne liquids such as saline solution
Deng, for example, the water of predetermined amount or other aqueous solutions, to obtain the gelatinized product again with required water content.
One example provides the method for delivering or giving object substance, and this method includes providing such as embodiment
Described in contain acellular tissue extract and optionally one or more substances (such as treat or cosmetic material or reagent)
Medical aquogel, and hydrogel is administered on the skin of object.Object can be patient or need any of the substance
Other objects, such as human or animal.By the way that hydrogel is administered on skin, substance by dermal delivery, preferably by control and/
Or extended release rate is delivered.
One example provides the method for substance to be delivered to object, and this method includes providing such as institute in embodiment
That states contains the doctor of acellular tissue extract and optionally one or more substances (such as treatment or cosmetic material or reagent)
With hydrogel, and hydrogel is injected to object.Injection or more specifically give approach can be it is subcutaneous or intramuscular.
One example provides the method for treating skin wound or other damages or injury, and the method includes inciting somebody to action this
Medical product described in text is administered in wound, damage or injury.One specific example, which is provided, is covered with transplanting for treating
The method of the skin wound of object such as skin graft (such as mish graft object or complete thick graft), the method includes will herein
The medical product is applied on graft.
Transplanting, which refers to, from a position of body to be moved to another position for tissue or moves from another person
Surgical procedure, without carrying blood supply.On the contrary, graft can generate new blood supply after placing.Autograft
It is usually not considered as with isograft external, therefore rejection will not be caused.Allograft and xenogenesis move
Plant is considered exotic and is ostracised by receptor.
Dermatoplasty is commonly used in treatment due to wound, burn, infection or caused skin loss of performing the operation.In skin damage
In the case where, it can be removed, and new skin can be transplanted to its position.Dermatoplasty can reduce required treatment and
Hospital course, and function and appearance can also be improved.There are two types of the skin grafts of type: middle thickness (split-
Thickness) skin graft (epidermis+some dermis) and full thickness skin transplantation object (epidermis+entire dermis thickness).
Mish graft object is aperture to allow the complete thick or part pachydermia piece of drain and expansion.Mish graft object is available
In many positions on body, because they can comply with uneven surface.They can be placed on the position of overexercise
It sets, because they can be stitched into following wound bed.In addition, their aperture is to be likely to accumulate in below graft
Fluid provides outlet, this helps to reduce tension and infection risk and the vascularization for improving graft.
Before medical product is administered on skin, product can be pre-processed, i.e., wet or wetting is general to use
Aqueous solution carries out.Wet or wetting can be carried out for example by using water or customary physiological saline solution, the customary physiological
Saline solution is usually 0.90%w/w NaCl solution, and osmotic pressure is about 308mOsm/l.Also other kinds of water can be used
Property solution, such as the saline solution with various concentration.Wet or wet material enhances contact and material piece with skin
Plasticity.
Embodiment
Select polyethylene glycol and trehalose as cryoprotector, because especially detecting collaboration effect in the redisperse stage
It answers.Preparation contains only polyethylene glycol, contains only trehalose and contains the NFC water of polyethylene glycol and trehalose as cryoprotector
Gel is simultaneously freeze-dried.It adds water in all samples in a similar way, but only containing polyethylene glycol and trehalose
Gel is melted into gel form appropriate to hydrogel again, that is, gel chemical conversion and similar form before freeze-drying again.This can pass through
Visual inspection is immediately detected.The precipitating of hydrogel is not detected.Only containing polyethylene glycol or only containing the water-setting of trehalose
Glue sample is melted into uniform gel form without gel again, the result is that paste and granular, this is not suitable for further studying.
In addition, hydrogel precipitates and is being free of cryoprotector or is containing only polyethylene glycol when sample to be placed in vial overnight
Or it contains only in the bottle of trehalose and isolates clearly visible water phase, but not in the bottle containing polyethylene glycol and trehalose
Isolate clearly visible water phase.
It finds in testing and shows that the NFC hydrogel of TEMPO oxidation can be successfully freeze-dried and be divided again
Dissipate into form of hydrogels.It is different from the preparation without cryoprotector PEG6000 and trehalose, used cryoprotector
PEG6000 and trehalose significantly improve the storage and loss of the NFC hydrogel of rehydration and redisperse after freeze-drying together
Modulus.In rehydration, the viscosity of the NFC hydrogel of the freeze-drying with excipient is also retained.
As described herein, adipose tissue extract is mixed with about 3.2% and 6% (w/w) nanometer fibril cellulose gel
And it is freeze-dried.Redispersible desciccate is obtained, shows biology present in initial adipose tissue extract
Activity.
These discoveries show that cryoprotector facilitates the structure that NFC fiber is kept in freezing dry process.Therefore,
The generation of NFC aeroge does not significantly change the rheological equationm of state.In addition, before and after lyophilization, bioactive compound
Bioactive substance release profiles it is similar.This is the feature that tissue extract preparation is highly desirable to, because sensitive for hydrolysis
Tissue extract, the drying regime of aeroge can increase the shelf-life of product.Aeroge can easily rehydration be simultaneously
It gives when needed.
Claims (19)
1. a kind of method that the acellular tissue extract in the hydrogel comprising nanometer fibril cellulose is dried, institute
The method of stating includes:
Hydrogel comprising nanometer fibril cellulose is provided,
Acellular tissue extract comprising bioactive substance mixture is provided,
Polyethylene glycol is provided,
Trehalose is provided,
Hydrogel, acellular tissue extract, polyethylene glycol and trehalose are mixed to obtain mixture, and
Mixture is freeze-dried to obtain the nothing of the drying in the hydrogel of the drying comprising nanometer fibril cellulose
Cell tissue extract.
2. the method for claim 1, wherein the acellular tissue extract is obtained from the group directly obtained from body
It knits.
3. method according to claim 1 or 2, wherein the acellular tissue extract is obtained from the cell of culture, such as obtains
From conditioned medium.
4. method as described in any one of the preceding claims, wherein the acellular tissue extract is that adipose tissue mentions
Object, such as human fat tissue extract are taken, the adipose tissue extract preferably at least includes VEGF, FGF-2 and IGF-1.
5. method as described in any one of the preceding claims, wherein calculated with the gross mass of mixture, in the mixture
The dry content range of acellular tissue extract is 0.01-10% (w/w), for example, 0.1-5% (w/w).
6. method as described in any one of the preceding claims, wherein calculated with the gross mass of mixture, the mixture packet
The trehalose of polyethylene glycol and/or 0.05-1.0 (w/w) containing 0.1-2% (w/w).
7. method as described in any one of the preceding claims, wherein the nanometer fibril cellulose is when being dispersed in water
At least 2000mPas, for example, at least 3000mPas measured under the consistency of 0.8% (w/w) and 10rpm is provided, such as extremely
Few 10000mPas, such as the brookfield viscosity of 2000-20000mPas.
8. method as described in any one of the preceding claims, wherein the nanometer fibril before freeze-drying, in the hydrogel
The concentration range of cellulose is 0.5-10%, such as 2-8%, such as 3-7%.
9. method as described in any one of the preceding claims, wherein the nanometer fibril cellulose is selected from anion-modified
Nanometer fibril cellulose, cation-modified nanometer fibril cellulose and unmodified nanometer fibril cellulose and TEMPO
The nanometer fibril cellulose of oxidation.
10. method as described in any one of the preceding claims, wherein the freeze-drying is lasting to carry out the water until dry
The water content of gel is 10% or lower, such as 2-10% (w/w), such as 2-5% (w/w).
11. a kind of water-setting of the drying comprising nanometer fibril cellulose, acellular tissue extract, polyethylene glycol and trehalose
Glue, the acellular tissue extract include the mixture of bioactive substance, wherein the water content of dry hydrogel is
10% (w/w) or lower, such as 2-10% (w/w), such as 2-8% (w/w).
12. the hydrogel of the drying comprising nanometer fibril cellulose as claimed in claim 11, wherein the water-setting of the drying
The dry content range of acellular tissue extract is 0.1-65% (w/w) in glue, for example, 0.1-50% (w/w), such as 1-25%
(w/w)。
13. the hydrogel of the drying comprising nanometer fibril cellulose as described in claim 11 or 12, wherein in dry water
In gel, polyethyleneglycol content range is 1-20% (w/w) and/or the content range of trehalose is 0.5-10% (w/w).
14. the hydrogel of the drying comprising nanometer fibril cellulose as described in any one of claim 11-13, wherein institute
It states acellular tissue extract and is obtained from the tissue directly obtained from body.
15. the hydrogel of the drying comprising nanometer fibril cellulose as described in any one of claim 11-13, wherein institute
The cell that acellular tissue extract is obtained from culture is stated, such as obtained from conditioned medium.
16. the hydrogel of the drying comprising nanometer fibril cellulose as described in any one of claim 11-15, wherein institute
Stating acellular tissue extract is adipose tissue extract, such as human fat tissue extract, and the adipose tissue extract is excellent
Choosing includes at least VEGF, FGF-2 and IGF-1.
17. the hydrogel of the drying comprising nanometer fibril cellulose as described in any one of claim 11-16, wherein institute
It states nanometer fibril cellulose and is provided when being dispersed in water and measured at least under the consistency of 0.8% (w/w) and 10rpm
2000mPas, for example, at least 3000mPas, for example, at least 10000mPas, such as the Bu Shi of 2000-20000mPas
Viscosity.
18. the hydrogel of the drying comprising nanometer fibril cellulose as described in any one of claim 11-17, wherein institute
It states nanometer fibril cellulose and is selected from anion-modified nanometer fibril cellulose, cation-modified nanometer fibril cellulose and not
Modified nanometer fibril cellulose and the nanometer fibril cellulose of TEMPO oxidation.
19. the hydrogel of the drying comprising nanometer fibril cellulose as described in any one of claim 11-18, the drying
Hydrogel use as method of any of claims 1-10 obtain.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16397538.6 | 2016-12-15 | ||
EP16397538.6A EP3335696B1 (en) | 2016-12-15 | 2016-12-15 | A method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract |
PCT/FI2017/050900 WO2018109282A1 (en) | 2016-12-15 | 2017-12-15 | A method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110234314A true CN110234314A (en) | 2019-09-13 |
Family
ID=57714501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780078102.7A Pending CN110234314A (en) | 2016-12-15 | 2017-12-15 | The method of dry acellular tissue extract and the dried hydrogel comprising nanometer fibril cellulose and acellular tissue extract in the hydrogel comprising nanometer fibril cellulose |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190343889A1 (en) |
EP (1) | EP3335696B1 (en) |
JP (1) | JP7162307B2 (en) |
CN (1) | CN110234314A (en) |
DK (1) | DK3335696T3 (en) |
WO (1) | WO2018109282A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113072716A (en) * | 2021-03-17 | 2021-07-06 | 武汉理工大学 | Preparation method of photo-crosslinked chitosan hydrogel |
CN114026223A (en) * | 2019-06-24 | 2022-02-08 | 芬欧汇川集团 | Transplantable cell composition comprising eukaryotic cells in a nanofibrillar cellulose hydrogel, method for the preparation thereof and use of nanofibrillar cellulose |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
JP5965409B2 (en) | 2010-12-08 | 2016-08-03 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | Integrated system for assessing wound exudate |
ES2748519T3 (en) | 2010-12-08 | 2020-03-17 | Convatec Technologies Inc | Wound exudate system accessory |
GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
EP2935688A2 (en) | 2012-12-20 | 2015-10-28 | ConvaTec Technologies Inc. | Processing of chemically modified cellulosic fibres |
KR102162352B1 (en) * | 2014-05-30 | 2020-10-07 | 보레가드 에이에스 | Microfibrillated cellulose |
KR20190013725A (en) | 2016-03-30 | 2019-02-11 | 컨바텍 테크놀러지스 인크 | Detection of microbial infection in wound |
US20230213525A1 (en) | 2016-03-30 | 2023-07-06 | Qualizyme Diagnostics Gmbh & Co Kg | Detecting microbial infection in wounds |
US11266774B2 (en) | 2016-07-08 | 2022-03-08 | Convatec Technologies Inc. | Fluid collection apparatus |
KR20190026858A (en) | 2016-07-08 | 2019-03-13 | 컨바텍 테크놀러지스 인크 | Flexible negative pressure system |
CN109689005B (en) | 2016-07-08 | 2022-03-04 | 康沃特克科技公司 | Fluid flow sensing |
DK3335695T3 (en) | 2016-12-15 | 2020-04-20 | Upm Kymmene Corp | Process for freeze-drying hydrogel comprising nanofibrillar cellulose, freeze-dried medical hydrogel comprising nanofibrillar cellulose and hydrogel comprising nanofibrillar cellulose |
JP7319793B2 (en) * | 2019-03-05 | 2023-08-02 | 第一工業製薬株式会社 | Subcutaneous or Submucosal Bulking Agent |
EP3771470A1 (en) * | 2019-07-29 | 2021-02-03 | UPM-Kymmene Corporation | Medical hydrogel comprising nanofibrillar cellulose, tailored wound dressing, and methods for preparing thereof |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
CN111544309B (en) * | 2020-05-27 | 2022-04-29 | 和携科技有限公司 | Bioactive substance freeze-dried solid mask and preparation method thereof |
US20220403309A1 (en) * | 2021-06-16 | 2022-12-22 | Upside Foods, Inc. | Plant fat-based scaffolds for the growth of cell-based meats and methods of making such products |
US11730861B2 (en) | 2021-10-14 | 2023-08-22 | The Methodist Hospital System | Hydrogel devices and methods of making and use thereof |
EP4227401A1 (en) * | 2022-02-11 | 2023-08-16 | UPM-Kymmene Corporation | An ex vivo tumour immune microenvironment model, a method for preserving a tumour-specific immune cell profile in an ex vivo tumour immune microenvironment model and use of nanofibrillar cellulose |
WO2024064887A2 (en) * | 2022-09-23 | 2024-03-28 | Cal Poly Corporation | Development of solid-state storage of complex biochemical systems |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874043A (en) * | 2007-11-26 | 2010-10-27 | 国立大学法人东京大学 | Cellulose nanofiber and process for production thereof, and cellulose nanofiber dispersion |
CN102143755A (en) * | 2008-09-08 | 2011-08-03 | 蒂莫·伊利科米 | Methods and means for soft tissue engineering |
WO2013072563A1 (en) * | 2011-11-15 | 2013-05-23 | Upm-Kymmene Corporation | Drug delivery system for sustained delivery of bioactive agents |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI105112B (en) | 1997-01-03 | 2000-06-15 | Megatrex Oy | Method and apparatus for defibrating fibrous material |
JP2011026202A (en) * | 2007-11-21 | 2011-02-10 | Masayuki Ishihara | Sustained release medicine-including carrier and pharmaceutical composition containing the same |
FI20095638A0 (en) * | 2009-06-09 | 2009-06-09 | Valtion Teknillinen | Hydrophobins for dispersing active substances |
GB0916031D0 (en) * | 2009-09-14 | 2009-10-28 | Univ Nottingham | Cellulose nanoparticle aerogels,hydrogels and organogels |
CZ307195B6 (en) * | 2013-11-18 | 2018-03-14 | František Trnka | A pharmaceutical composition comprising a mixture of proenzymes and enzymes |
DK3335695T3 (en) * | 2016-12-15 | 2020-04-20 | Upm Kymmene Corp | Process for freeze-drying hydrogel comprising nanofibrillar cellulose, freeze-dried medical hydrogel comprising nanofibrillar cellulose and hydrogel comprising nanofibrillar cellulose |
-
2016
- 2016-12-15 EP EP16397538.6A patent/EP3335696B1/en active Active
- 2016-12-15 DK DK16397538.6T patent/DK3335696T3/en active
-
2017
- 2017-12-15 JP JP2019554023A patent/JP7162307B2/en active Active
- 2017-12-15 CN CN201780078102.7A patent/CN110234314A/en active Pending
- 2017-12-15 US US16/466,772 patent/US20190343889A1/en not_active Abandoned
- 2017-12-15 WO PCT/FI2017/050900 patent/WO2018109282A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101874043A (en) * | 2007-11-26 | 2010-10-27 | 国立大学法人东京大学 | Cellulose nanofiber and process for production thereof, and cellulose nanofiber dispersion |
CN102143755A (en) * | 2008-09-08 | 2011-08-03 | 蒂莫·伊利科米 | Methods and means for soft tissue engineering |
WO2013072563A1 (en) * | 2011-11-15 | 2013-05-23 | Upm-Kymmene Corporation | Drug delivery system for sustained delivery of bioactive agents |
Non-Patent Citations (1)
Title |
---|
STEVEN J. PRESTRELSKI等: "Separation of Freezing- and Drying-Induced Denaturation of Lyophilized Proteins Using Stress-Specific Stabilization: II. Structural Studies Using Infrared Spectroscopy", 《ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114026223A (en) * | 2019-06-24 | 2022-02-08 | 芬欧汇川集团 | Transplantable cell composition comprising eukaryotic cells in a nanofibrillar cellulose hydrogel, method for the preparation thereof and use of nanofibrillar cellulose |
CN113072716A (en) * | 2021-03-17 | 2021-07-06 | 武汉理工大学 | Preparation method of photo-crosslinked chitosan hydrogel |
Also Published As
Publication number | Publication date |
---|---|
DK3335696T3 (en) | 2020-03-16 |
EP3335696B1 (en) | 2019-12-18 |
EP3335696A1 (en) | 2018-06-20 |
US20190343889A1 (en) | 2019-11-14 |
WO2018109282A1 (en) | 2018-06-21 |
JP7162307B2 (en) | 2022-10-28 |
JP2020502274A (en) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110234314A (en) | The method of dry acellular tissue extract and the dried hydrogel comprising nanometer fibril cellulose and acellular tissue extract in the hydrogel comprising nanometer fibril cellulose | |
CN110087633A (en) | The method of the dry hydrogel comprising nanometer fibril cellulose and the hydrogel of the drying comprising nanometer fibril cellulose | |
JP7106539B2 (en) | medical hydrogel | |
EP2468307B1 (en) | Degradation-stabilised, biocompatible collagen matrices | |
BR112017022045B1 (en) | COMPOSITION FOR PSEUDOPLASTIC MICROGEL MATRIXES | |
Liu et al. | Bioactive wound dressing based on decellularized tendon and GelMA with incorporation of PDA-loaded asiaticoside nanoparticles for scarless wound healing | |
CN112755240B (en) | Medical hydrogel comprising nanofibrillar cellulose, custom wound dressing and method for preparing same | |
Xu et al. | Advanced polymer hydrogels that promote diabetic ulcer healing: mechanisms, classifications, and medical applications | |
EP3494791B1 (en) | Treatment of skin-related symptoms of ehlers-danlos syndrome with poly-n-acetylglucosamine nanofibers | |
JP2021020070A5 (en) | ||
WO2021109979A1 (en) | Flowable fibrinogen thrombin paste | |
US20220118001A1 (en) | Methods and uses of natural based compositions | |
CN115670944B (en) | Microsponge with anti-aging effect and preparation method and application thereof | |
US20220249550A1 (en) | Preparation and use of tissue matrix derived powder | |
US20230338455A1 (en) | Pharmaceutical composition in the form of a hydrogel comprising orange-derived extracellular vesicles | |
KR20230105384A (en) | Filler composition for anti-wrinkle of skin comprising exosome derived from stem cell and temperature-sensitive biocompatible polymer, and Method for manufacturing thereof | |
Beihaghia et al. | Development of Skin Diseases Treatment based on Exosome Derived from Plants, Humans, Medicinal Algae and Fungi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40014317 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190913 |